WO2013163344A1 - 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
- Google Patents
2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Download PDF
Info
Publication number
WO2013163344A1
WO2013163344A1
PCT/US2013/038064
US2013038064W
WO2013163344A1
WO 2013163344 A1
WO2013163344 A1
WO 2013163344A1
US 2013038064 W
US2013038064 W
US 2013038064W
WO 2013163344 A1
WO2013163344 A1
WO 2013163344A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
compound
polymorphic form
rta
use according
Prior art date
2012-04-27
Application number
PCT/US2013/038064
Other languages
French (fr )
Inventor
Eric Anderson
Andrea Decker
Xiaofeng Liu
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2012-04-27
Filing date
2013-04-24
Publication date
2013-10-31
2013-04-24
Priority to SI201330749T
priority
Critical
patent/SI2841445T1/en
2013-04-24
Priority to CN201380034275.0A
priority
patent/CN104395332B/en
2013-04-24
Priority to EP17175885.7A
priority
patent/EP3444261B1/en
2013-04-24
Priority to PL13720708T
priority
patent/PL2841445T3/en
2013-04-24
Application filed by Reata Pharmaceuticals, Inc.
filed
Critical
Reata Pharmaceuticals, Inc.
2013-04-24
Priority to AU2013251602A
priority
patent/AU2013251602B2/en
2013-04-24
Priority to MYPI2014003024A
priority
patent/MY172750A/en
2013-04-24
Priority to BR112014026640-9A
priority
patent/BR112014026640B1/en
2013-04-24
Priority to ES13720708.0T
priority
patent/ES2634315T3/en
2013-04-24
Priority to EA201491972A
priority
patent/EA030468B1/en
2013-04-24
Priority to JP2015509119A
priority
patent/JP6410710B2/en
2013-04-24
Priority to UAA201412683A
priority
patent/UA116209C2/en
2013-04-24
Priority to NZ630222A
priority
patent/NZ630222A/en
2013-04-24
Priority to MEP-2017-178A
priority
patent/ME02926B/en
2013-04-24
Priority to RS20170770A
priority
patent/RS56154B1/en
2013-04-24
Priority to DK13720708.0T
priority
patent/DK2841445T3/en
2013-04-24
Priority to PL17175885T
priority
patent/PL3444261T3/en
2013-04-24
Priority to SG11201406868XA
priority
patent/SG11201406868XA/en
2013-04-24
Priority to CA2869783A
priority
patent/CA2869783C/en
2013-04-24
Priority to LTEP13720708.0T
priority
patent/LT2841445T/en
2013-04-24
Priority to KR1020147032968A
priority
patent/KR102101774B1/en
2013-04-24
Priority to MX2014013076A
priority
patent/MX357060B/en
2013-04-24
Priority to EP13720708.0A
priority
patent/EP2841445B1/en
2013-10-31
Publication of WO2013163344A1
publication
Critical
patent/WO2013163344A1/en
2014-10-09
Priority to ZA2014/07326A
priority
patent/ZA201407326B/en
2014-10-22
Priority to IL235275A
priority
patent/IL235275B/en
2015-08-05
Priority to HK15107527.0A
priority
patent/HK1207086A1/en
2015-08-05
Priority to HK15107525.2A
priority
patent/HK1207085A1/en
2017-08-22
Priority to HRP20171275TT
priority
patent/HRP20171275T1/en
2017-09-12
Priority to CY20171100959T
priority
patent/CY1119333T1/en
2021-03-26
Priority to CY20211100266T
priority
patent/CY1124130T1/en
2024-04-17
Priority to FR24C1015C
priority
patent/FR24C1015I1/en
2024-04-18
Priority to FIC20240012C
priority
patent/FIC20240012I1/en
2024-05-29
Priority to NL301276C
priority
patent/NL301276I2/en
Links
238000000034
method
Methods
0.000
title
claims
abstract
description
145
WPTTVJLTNAWYAO-KPOXMGGZSA-N
Bardoxolone methyl
Chemical group
C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C
WPTTVJLTNAWYAO-KPOXMGGZSA-N
0.000
title
description
11
150000001875
compounds
Chemical class
0.000
claims
abstract
description
197
239000008194
pharmaceutical composition
Substances
0.000
claims
abstract
description
139
238000002360
preparation method
Methods
0.000
claims
abstract
description
15
230000000694
effects
Effects
0.000
claims
description
168
238000011282
treatment
Methods
0.000
claims
description
104
208000037265
diseases, disorders, signs and symptoms
Diseases
0.000
claims
description
92
239000012453
solvate
Substances
0.000
claims
description
92
WEVYAHXRMPXWCK-UHFFFAOYSA-N
Acetonitrile
Chemical compound
CC#N
WEVYAHXRMPXWCK-UHFFFAOYSA-N
0.000
claims
description
65
201000010099
disease
Diseases
0.000
claims
description
64
206010061218
Inflammation
Diseases
0.000
claims
description
59
230000004054
inflammatory process
Effects
0.000
claims
description
58
239000000203
mixture
Substances
0.000
claims
description
50
208000017520
skin disease
Diseases
0.000
claims
description
49
201000004624
Dermatitis
Diseases
0.000
claims
description
48
206010028980
Neoplasm
Diseases
0.000
claims
description
45
210000004072
lung
Anatomy
0.000
claims
description
41
210000004185
liver
Anatomy
0.000
claims
description
37
201000011510
cancer
Diseases
0.000
claims
description
35
230000036542
oxidative stress
Effects
0.000
claims
description
33
241000282414
Homo sapiens
Species
0.000
claims
description
32
239000003814
drug
Substances
0.000
claims
description
29
230000001684
chronic effect
Effects
0.000
claims
description
28
230000001154
acute effect
Effects
0.000
claims
description
27
238000002512
chemotherapy
Methods
0.000
claims
description
27
206010012601
diabetes mellitus
Diseases
0.000
claims
description
27
208000035475
disorder
Diseases
0.000
claims
description
27
238000001959
radiotherapy
Methods
0.000
claims
description
27
238000000634
powder X-ray diffraction
Methods
0.000
claims
description
26
150000003839
salts
Chemical class
0.000
claims
description
24
229940079593
drug
Drugs
0.000
claims
description
23
229910016523
CuKa
Inorganic materials
0.000
claims
description
22
210000004369
blood
Anatomy
0.000
claims
description
20
239000008280
blood
Substances
0.000
claims
description
20
208000023275
Autoimmune disease
Diseases
0.000
claims
description
19
206010028116
Mucosal inflammation
Diseases
0.000
claims
description
19
201000010927
Mucositis
Diseases
0.000
claims
description
19
239000003795
chemical substances by application
Substances
0.000
claims
description
19
210000004556
brain
Anatomy
0.000
claims
description
18
201000004681
Psoriasis
Diseases
0.000
claims
description
17
210000003734
kidney
Anatomy
0.000
claims
description
16
210000003491
skin
Anatomy
0.000
claims
description
16
208000019693
Lung disease
Diseases
0.000
claims
description
15
206010040047
Sepsis
Diseases
0.000
claims
description
15
208000027418
Wounds and injury
Diseases
0.000
claims
description
15
239000000243
solution
Substances
0.000
claims
description
15
239000000725
suspension
Substances
0.000
claims
description
15
238000011200
topical administration
Methods
0.000
claims
description
15
208000011231
Crohn disease
Diseases
0.000
claims
description
14
230000005865
ionizing radiation
Effects
0.000
claims
description
14
201000004384
Alopecia
Diseases
0.000
claims
description
13
210000003169
central nervous system
Anatomy
0.000
claims
description
13
208000030533
eye disease
Diseases
0.000
claims
description
13
208000006934
radiodermatitis
Diseases
0.000
claims
description
13
206010039073
rheumatoid arthritis
Diseases
0.000
claims
description
13
208000022559
Inflammatory bowel disease
Diseases
0.000
claims
description
12
239000004480
active ingredient
Substances
0.000
claims
description
12
238000000113
differential scanning calorimetry
Methods
0.000
claims
description
12
230000002265
prevention
Effects
0.000
claims
description
12
239000008159
sesame oil
Substances
0.000
claims
description
12
235000011803
sesame oil
Nutrition
0.000
claims
description
12
208000006545
Chronic Obstructive Pulmonary Disease
Diseases
0.000
claims
description
11
208000002780
macular degeneration
Diseases
0.000
claims
description
11
206010053159
Organ failure
Diseases
0.000
claims
description
10
231100000360
alopecia
Toxicity
0.000
claims
description
10
235000019504
cigarettes
Nutrition
0.000
claims
description
9
210000001072
colon
Anatomy
0.000
claims
description
9
210000004927
skin cell
Anatomy
0.000
claims
description
9
239000000779
smoke
Substances
0.000
claims
description
9
206010052428
Wound
Diseases
0.000
claims
description
8
239000000839
emulsion
Substances
0.000
claims
description
8
208000019423
liver disease
Diseases
0.000
claims
description
8
210000003205
muscle
Anatomy
0.000
claims
description
8
201000008482
osteoarthritis
Diseases
0.000
claims
description
8
208000005069
pulmonary fibrosis
Diseases
0.000
claims
description
8
208000012641
Pigmentation disease
Diseases
0.000
claims
description
7
206010035664
Pneumonia
Diseases
0.000
claims
description
7
201000008937
atopic dermatitis
Diseases
0.000
claims
description
7
210000000988
bone and bone
Anatomy
0.000
claims
description
7
230000008798
inflammatory stress
Effects
0.000
claims
description
7
206010025135
lupus erythematosus
Diseases
0.000
claims
description
7
210000000813
small intestine
Anatomy
0.000
claims
description
7
GHASVSINZRGABV-UHFFFAOYSA-N
Fluorouracil
Chemical compound
FC1=CNC(=O)NC1=O
GHASVSINZRGABV-UHFFFAOYSA-N
0.000
claims
description
6
206010033645
Pancreatitis
Diseases
0.000
claims
description
6
208000006673
asthma
Diseases
0.000
claims
description
6
239000003937
drug carrier
Substances
0.000
claims
description
6
229960002949
fluorouracil
Drugs
0.000
claims
description
6
210000002429
large intestine
Anatomy
0.000
claims
description
6
239000002674
ointment
Substances
0.000
claims
description
6
210000000496
pancreas
Anatomy
0.000
claims
description
6
208000010412
Glaucoma
Diseases
0.000
claims
description
5
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
Chemical compound
O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
0.000
claims
description
5
206010042496
Sunburn
Diseases
0.000
claims
description
5
239000006071
cream
Substances
0.000
claims
description
5
229960003668
docetaxel
Drugs
0.000
claims
description
5
210000000871
endothelium corneal
Anatomy
0.000
claims
description
5
210000003238
esophagus
Anatomy
0.000
claims
description
5
210000004392
genitalia
Anatomy
0.000
claims
description
5
238000001802
infusion
Methods
0.000
claims
description
5
239000006210
lotion
Substances
0.000
claims
description
5
230000019612
pigmentation
Effects
0.000
claims
description
5
210000002784
stomach
Anatomy
0.000
claims
description
5
210000001685
thyroid gland
Anatomy
0.000
claims
description
5
208000002874
Acne Vulgaris
Diseases
0.000
claims
description
4
201000009030
Carcinoma
Diseases
0.000
claims
description
4
201000003883
Cystic fibrosis
Diseases
0.000
claims
description
4
206010012438
Dermatitis atopic
Diseases
0.000
claims
description
4
208000009329
Graft vs Host Disease
Diseases
0.000
claims
description
4
206010025323
Lymphomas
Diseases
0.000
claims
description
4
206010027406
Mesothelioma
Diseases
0.000
claims
description
4
208000034578
Multiple myelomas
Diseases
0.000
claims
description
4
206010035226
Plasma cell myeloma
Diseases
0.000
claims
description
4
206010039491
Sarcoma
Diseases
0.000
claims
description
4
201000010208
Seminoma
Diseases
0.000
claims
description
4
206010046851
Uveitis
Diseases
0.000
claims
description
4
206010000496
acne
Diseases
0.000
claims
description
4
210000000481
breast
Anatomy
0.000
claims
description
4
210000003679
cervix uteri
Anatomy
0.000
claims
description
4
210000004696
endometrium
Anatomy
0.000
claims
description
4
210000000232
gallbladder
Anatomy
0.000
claims
description
4
208000024908
graft versus host disease
Diseases
0.000
claims
description
4
125000001475
halogen functional group
Chemical group
0.000
claims
description
4
210000003128
head
Anatomy
0.000
claims
description
4
238000002347
injection
Methods
0.000
claims
description
4
239000007924
injection
Substances
0.000
claims
description
4
210000000867
larynx
Anatomy
0.000
claims
description
4
208000032839
leukemia
Diseases
0.000
claims
description
4
201000001441
melanoma
Diseases
0.000
claims
description
4
210000002200
mouth mucosa
Anatomy
0.000
claims
description
4
210000002850
nasal mucosa
Anatomy
0.000
claims
description
4
210000003739
neck
Anatomy
0.000
claims
description
4
239000003921
oil
Substances
0.000
claims
description
4
235000019198
oils
Nutrition
0.000
claims
description
4
210000001672
ovary
Anatomy
0.000
claims
description
4
210000002307
prostate
Anatomy
0.000
claims
description
4
210000000952
spleen
Anatomy
0.000
claims
description
4
208000003265
stomatitis
Diseases
0.000
claims
description
4
210000001550
testis
Anatomy
0.000
claims
description
4
208000009043
Chemical Burns
Diseases
0.000
claims
description
3
206010010741
Conjunctivitis
Diseases
0.000
claims
description
3
206010010744
Conjunctivitis allergic
Diseases
0.000
claims
description
3
206010011985
Decubitus ulcer
Diseases
0.000
claims
description
3
206010012434
Dermatitis allergic
Diseases
0.000
claims
description
3
206010012688
Diabetic retinal oedema
Diseases
0.000
claims
description
3
206010012689
Diabetic retinopathy
Diseases
0.000
claims
description
3
206010056340
Diabetic ulcer
Diseases
0.000
claims
description
3
208000003556
Dry Eye Syndromes
Diseases
0.000
claims
description
3
206010013774
Dry eye
Diseases
0.000
claims
description
3
206010014989
Epidermolysis bullosa
Diseases
0.000
claims
description
3
208000033051
Fuchs endothelial corneal dystrophy
Diseases
0.000
claims
description
3
206010020649
Hyperkeratosis
Diseases
0.000
claims
description
3
201000009794
Idiopathic Pulmonary Fibrosis
Diseases
0.000
claims
description
3
208000004210
Pressure Ulcer
Diseases
0.000
claims
description
3
208000000453
Skin Neoplasms
Diseases
0.000
claims
description
3
208000028990
Skin injury
Diseases
0.000
claims
description
3
208000002847
Surgical Wound
Diseases
0.000
claims
description
3
206010053615
Thermal burn
Diseases
0.000
claims
description
3
208000000558
Varicose Ulcer
Diseases
0.000
claims
description
3
206010047642
Vitiligo
Diseases
0.000
claims
description
3
208000002205
allergic conjunctivitis
Diseases
0.000
claims
description
3
208000024998
atopic conjunctivitis
Diseases
0.000
claims
description
3
208000010668
atopic eczema
Diseases
0.000
claims
description
3
208000010217
blepharitis
Diseases
0.000
claims
description
3
201000011190
diabetic macular edema
Diseases
0.000
claims
description
3
210000003780
hair follicle
Anatomy
0.000
claims
description
3
230000003676
hair loss
Effects
0.000
claims
description
3
239000007902
hard capsule
Substances
0.000
claims
description
3
208000036971
interstitial lung disease 2
Diseases
0.000
claims
description
3
238000001990
intravenous administration
Methods
0.000
claims
description
3
230000010412
perfusion
Effects
0.000
claims
description
3
201000000849
skin cancer
Diseases
0.000
claims
description
3
239000007901
soft capsule
Substances
0.000
claims
description
3
239000007962
solid dispersion
Substances
0.000
claims
description
3
239000006188
syrup
Substances
0.000
claims
description
3
235000020357
syrup
Nutrition
0.000
claims
description
3
208000018380
Chemical injury
Diseases
0.000
claims
description
2
208000010706
fatty liver disease
Diseases
0.000
claims
description
2
208000006454
hepatitis
Diseases
0.000
claims
description
2
231100000283
hepatitis
Toxicity
0.000
claims
description
2
238000001361
intraarterial administration
Methods
0.000
claims
description
2
150000002632
lipids
Chemical class
0.000
claims
description
2
231100000241
scar
Toxicity
0.000
claims
description
2
210000003932
urinary bladder
Anatomy
0.000
claims
description
2
RJCWBNBKOKFWNY-IDPLTSGASA-N
n-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
Chemical compound
C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(NC(=O)C(F)(F)C)CC[C@]21C
RJCWBNBKOKFWNY-IDPLTSGASA-N
0.000
abstract
description
405
238000004519
manufacturing process
Methods
0.000
abstract
description
32
210000004027
cell
Anatomy
0.000
description
117
239000000523
sample
Substances
0.000
description
116
108090000623
proteins and genes
Proteins
0.000
description
67
101000588302
Homo sapiens Nuclear factor erythroid 2-related factor 2
Proteins
0.000
description
63
102100031701
Nuclear factor erythroid 2-related factor 2
Human genes
0.000
description
62
241000699670
Mus sp.
Species
0.000
description
56
241000700159
Rattus
Species
0.000
description
49
210000001519
tissue
Anatomy
0.000
description
49
102000004190
Enzymes
Human genes
0.000
description
44
108090000790
Enzymes
Proteins
0.000
description
44
229940088598
enzyme
Drugs
0.000
description
44
238000001228
spectrum
Methods
0.000
description
37
230000014509
gene expression
Effects
0.000
description
35
230000006698
induction
Effects
0.000
description
34
241001465754
Metazoa
Species
0.000
description
33
230000037396
body weight
Effects
0.000
description
33
241000282693
Cercopithecidae
Species
0.000
description
31
241000699666
Mus <mouse, genus>
Species
0.000
description
30
108060008682
Tumor Necrosis Factor
Proteins
0.000
description
30
102000000852
Tumor Necrosis Factor-alpha
Human genes
0.000
description
30
230000004913
activation
Effects
0.000
description
30
238000001144
powder X-ray diffraction data
Methods
0.000
description
30
230000002757
inflammatory effect
Effects
0.000
description
29
238000000003
thermogravimetry coupled to Fourier transform infrared spectroscopy
Methods
0.000
description
28
230000002354
daily effect
Effects
0.000
description
27
-1
cyclodextrans
Polymers
0.000
description
25
210000002381
plasma
Anatomy
0.000
description
25
238000001757
thermogravimetry curve
Methods
0.000
description
25
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
Dimethylsulphoxide
Chemical compound
CS(C)=O
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
0.000
description
24
RWSXRVCMGQZWBV-WDSKDSINSA-N
glutathione
Chemical compound
OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O
RWSXRVCMGQZWBV-WDSKDSINSA-N
0.000
description
24
239000003981
vehicle
Substances
0.000
description
24
231100000673
dose–response relationship
Toxicity
0.000
description
23
229910001868
water
Inorganic materials
0.000
description
23
230000001965
increasing effect
Effects
0.000
description
22
102000004127
Cytokines
Human genes
0.000
description
21
108090000695
Cytokines
Proteins
0.000
description
21
102000004169
proteins and genes
Human genes
0.000
description
21
MWUXSHHQAYIFBG-UHFFFAOYSA-N
Nitric oxide
Chemical compound
O=[N]
MWUXSHHQAYIFBG-UHFFFAOYSA-N
0.000
description
20
NOESYZHRGYRDHS-UHFFFAOYSA-N
insulin
Chemical compound
N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1
NOESYZHRGYRDHS-UHFFFAOYSA-N
0.000
description
20
108010018924
Heme Oxygenase-1
Proteins
0.000
description
19
102000002737
Heme Oxygenase-1
Human genes
0.000
description
19
108060001084
Luciferase
Proteins
0.000
description
19
239000005089
Luciferase
Substances
0.000
description
19
230000006870
function
Effects
0.000
description
19
235000018102
proteins
Nutrition
0.000
description
19
230000001225
therapeutic effect
Effects
0.000
description
19
108010076864
Nitric Oxide Synthase Type II
Proteins
0.000
description
18
239000002158
endotoxin
Substances
0.000
description
18
238000002474
experimental method
Methods
0.000
description
18
229920006008
lipopolysaccharide
Polymers
0.000
description
18
239000000463
material
Substances
0.000
description
18
108020004999
messenger RNA
Proteins
0.000
description
18
108010037462
Cyclooxygenase 2
Proteins
0.000
description
17
238000005079
FT-Raman
Methods
0.000
description
17
102000011779
Nitric Oxide Synthase Type II
Human genes
0.000
description
17
230000015572
biosynthetic process
Effects
0.000
description
17
230000002441
reversible effect
Effects
0.000
description
17
230000009885
systemic effect
Effects
0.000
description
17
XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances
O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
17
208000024172
Cardiovascular disease
Diseases
0.000
description
16
230000006378
damage
Effects
0.000
description
16
238000011156
evaluation
Methods
0.000
description
16
238000000338
in vitro
Methods
0.000
description
16
230000009467
reduction
Effects
0.000
description
16
WYURNTSHIVDZCO-UHFFFAOYSA-N
tetrahydrofuran
Substances
C1CCOC1
WYURNTSHIVDZCO-UHFFFAOYSA-N
0.000
description
16
102100038280
Prostaglandin G/H synthase 2
Human genes
0.000
description
15
238000001035
drying
Methods
0.000
description
15
230000005764
inhibitory process
Effects
0.000
description
15
230000000770
proinflammatory effect
Effects
0.000
description
15
239000002904
solvent
Substances
0.000
description
15
238000012360
testing method
Methods
0.000
description
15
201000006417
multiple sclerosis
Diseases
0.000
description
14
230000007170
pathology
Effects
0.000
description
14
JUJBNYBVVQSIOU-UHFFFAOYSA-M
sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate
Chemical compound
[Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1
JUJBNYBVVQSIOU-UHFFFAOYSA-M
0.000
description
14
108700032225
Antioxidant Response Elements
Proteins
0.000
description
13
XJLXINKUBYWONI-NNYOXOHSSA-N
NADP zwitterion
Chemical compound
NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1
XJLXINKUBYWONI-NNYOXOHSSA-N
0.000
description
13
239000002246
antineoplastic agent
Substances
0.000
description
13
230000008859
change
Effects
0.000
description
13
229940127089
cytotoxic agent
Drugs
0.000
description
13
238000011161
development
Methods
0.000
description
13
230000018109
developmental process
Effects
0.000
description
13
230000000670
limiting effect
Effects
0.000
description
13
210000002540
macrophage
Anatomy
0.000
description
13
229930027945
nicotinamide-adenine dinucleotide
Natural products
0.000
description
13
208000024891
symptom
Diseases
0.000
description
13
CSCPPACGZOOCGX-UHFFFAOYSA-N
Acetone
Chemical compound
CC(C)=O
CSCPPACGZOOCGX-UHFFFAOYSA-N
0.000
description
12
108010006654
Bleomycin
Proteins
0.000
description
12
AOJJSUZBOXZQNB-TZSSRYMLSA-N
Doxorubicin
Chemical compound
O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
AOJJSUZBOXZQNB-TZSSRYMLSA-N
0.000
description
12
208000001647
Renal Insufficiency
Diseases
0.000
description
12
208000025865
Ulcer
Diseases
0.000
description
12
125000004429
atom
Chemical group
0.000
description
12
238000006243
chemical reaction
Methods
0.000
description
12
229960003180
glutathione
Drugs
0.000
description
12
201000006370
kidney failure
Diseases
0.000
description
12
238000005259
measurement
Methods
0.000
description
12
206010015150
Erythema
Diseases
0.000
description
11
108010017324
STAT3 Transcription Factor
Proteins
0.000
description
11
102100024040
Signal transducer and activator of transcription 3
Human genes
0.000
description
11
230000003078
antioxidant effect
Effects
0.000
description
11
229960001561
bleomycin
Drugs
0.000
description
11
OYVAGSVQBOHSSS-UAPAGMARSA-O
bleomycin A2
Chemical compound
N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C
OYVAGSVQBOHSSS-UAPAGMARSA-O
0.000
description
11
208000020832
chronic kidney disease
Diseases
0.000
description
11
238000002648
combination therapy
Methods
0.000
description
11
238000001727
in vivo
Methods
0.000
description
11
230000002829
reductive effect
Effects
0.000
description
11
230000004044
response
Effects
0.000
description
11
230000000699
topical effect
Effects
0.000
description
11
210000004881
tumor cell
Anatomy
0.000
description
11
208000001072
type 2 diabetes mellitus
Diseases
0.000
description
11
230000035899
viability
Effects
0.000
description
11
201000001320
Atherosclerosis
Diseases
0.000
description
10
206010073306
Exposure to radiation
Diseases
0.000
description
10
WQZGKKKJIJFFOK-GASJEMHNSA-N
Glucose
Natural products
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-GASJEMHNSA-N
0.000
description
10
108010024636
Glutathione
Proteins
0.000
description
10
102000004877
Insulin
Human genes
0.000
description
10
108090001061
Insulin
Proteins
0.000
description
10
238000002835
absorbance
Methods
0.000
description
10
239000003963
antioxidant agent
Substances
0.000
description
10
239000002327
cardiovascular agent
Substances
0.000
description
10
229940125692
cardiovascular agent
Drugs
0.000
description
10
230000001413
cellular effect
Effects
0.000
description
10
230000002596
correlated effect
Effects
0.000
description
10
231100000321
erythema
Toxicity
0.000
description
10
238000009472
formulation
Methods
0.000
description
10
239000008103
glucose
Substances
0.000
description
10
230000028709
inflammatory response
Effects
0.000
description
10
208000014674
injury
Diseases
0.000
description
10
229940125396
insulin
Drugs
0.000
description
10
230000004770
neurodegeneration
Effects
0.000
description
10
208000015122
neurodegenerative disease
Diseases
0.000
description
10
238000003305
oral gavage
Methods
0.000
description
10
229940002612
prodrug
Drugs
0.000
description
10
239000000651
prodrug
Substances
0.000
description
10
238000003786
synthesis reaction
Methods
0.000
description
10
108091032973
(ribonucleotides)n+m
Proteins
0.000
description
9
208000024827
Alzheimer disease
Diseases
0.000
description
9
208000003456
Juvenile Arthritis
Diseases
0.000
description
9
JVTAAEKCZFNVCJ-UHFFFAOYSA-M
Lactate
Chemical compound
CC(O)C([O-])=O
JVTAAEKCZFNVCJ-UHFFFAOYSA-M
0.000
description
9
210000001744
T-lymphocyte
Anatomy
0.000
description
9
238000009826
distribution
Methods
0.000
description
9
208000002551
irritable bowel syndrome
Diseases
0.000
description
9
208000017169
kidney disease
Diseases
0.000
description
9
230000008569
process
Effects
0.000
description
9
241000894007
species
Species
0.000
description
9
208000011580
syndromic disease
Diseases
0.000
description
9
231100000041
toxicology testing
Toxicity
0.000
description
9
206010002556
Ankylosing Spondylitis
Diseases
0.000
description
8
206010009900
Colitis ulcerative
Diseases
0.000
description
8
XEKOWRVHYACXOJ-UHFFFAOYSA-N
Ethyl acetate
Chemical compound
CCOC(C)=O
XEKOWRVHYACXOJ-UHFFFAOYSA-N
0.000
description
8
241000282412
Homo
Species
0.000
description
8
102000004889
Interleukin-6
Human genes
0.000
description
8
108090001005
Interleukin-6
Proteins
0.000
description
8
206010059176
Juvenile idiopathic arthritis
Diseases
0.000
description
8
IMNFDUFMRHMDMM-UHFFFAOYSA-N
N-Heptane
Chemical compound
CCCCCCC
IMNFDUFMRHMDMM-UHFFFAOYSA-N
0.000
description
8
208000002193
Pain
Diseases
0.000
description
8
206010060862
Prostate cancer
Diseases
0.000
description
8
208000000236
Prostatic Neoplasms
Diseases
0.000
description
8
201000001263
Psoriatic Arthritis
Diseases
0.000
description
8
208000036824
Psoriatic arthropathy
Diseases
0.000
description
8
241000283984
Rodentia
Species
0.000
description
8
206010040844
Skin exfoliation
Diseases
0.000
description
8
201000006704
Ulcerative Colitis
Diseases
0.000
description
8
238000010521
absorption reaction
Methods
0.000
description
8
206010003246
arthritis
Diseases
0.000
description
8
230000008901
benefit
Effects
0.000
description
8
HVYWMOMLDIMFJA-DPAQBDIFSA-N
cholesterol
Chemical compound
C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2
HVYWMOMLDIMFJA-DPAQBDIFSA-N
0.000
description
8
230000035618
desquamation
Effects
0.000
description
8
230000002401
inhibitory effect
Effects
0.000
description
8
201000002215
juvenile rheumatoid arthritis
Diseases
0.000
description
8
210000003819
peripheral blood mononuclear cell
Anatomy
0.000
description
8
230000005855
radiation
Effects
0.000
description
8
239000011541
reaction mixture
Substances
0.000
description
8
239000007787
solid
Substances
0.000
description
8
238000002560
therapeutic procedure
Methods
0.000
description
8
231100000397
ulcer
Toxicity
0.000
description
8
RZRQJICXYQPEQJ-YKEYHJQHSA-N
(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-n-ethyl-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxamide
Chemical compound
C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)NCC)CC[C@]21C
RZRQJICXYQPEQJ-YKEYHJQHSA-N
0.000
description
7
108090000331
Firefly luciferases
Proteins
0.000
description
7
206010020772
Hypertension
Diseases
0.000
description
7
102000000589
Interleukin-1
Human genes
0.000
description
7
108010002352
Interleukin-1
Proteins
0.000
description
7
LCTONWCANYUPML-UHFFFAOYSA-M
Pyruvate
Chemical compound
CC(=O)C([O-])=O
LCTONWCANYUPML-UHFFFAOYSA-M
0.000
description
7
FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound
[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
7
208000006045
Spondylarthropathies
Diseases
0.000
description
7
108090000340
Transaminases
Proteins
0.000
description
7
102000040945
Transcription factor
Human genes
0.000
description
7
108091023040
Transcription factor
Proteins
0.000
description
7
ZMANZCXQSJIPKH-UHFFFAOYSA-N
Triethylamine
Chemical compound
CCN(CC)CC
ZMANZCXQSJIPKH-UHFFFAOYSA-N
0.000
description
7
238000003556
assay
Methods
0.000
description
7
WPYMKLBDIGXBTP-UHFFFAOYSA-N
benzoic acid
Chemical compound
OC(=O)C1=CC=CC=C1
WPYMKLBDIGXBTP-UHFFFAOYSA-N
0.000
description
7
239000000872
buffer
Substances
0.000
description
7
229910052799
carbon
Inorganic materials
0.000
description
7
208000019069
chronic childhood arthritis
Diseases
0.000
description
7
210000001508
eye
Anatomy
0.000
description
7
208000015181
infectious disease
Diseases
0.000
description
7
210000000056
organ
Anatomy
0.000
description
7
229940094443
oxytocics prostaglandins
Drugs
0.000
description
7
230000037361
pathway
Effects
0.000
description
7
230000036470
plasma concentration
Effects
0.000
description
7
230000035755
proliferation
Effects
0.000
description
7
229940076788
pyruvate
Drugs
0.000
description
7
201000005671
spondyloarthropathy
Diseases
0.000
description
7
238000003756
stirring
Methods
0.000
description
7
230000004083
survival effect
Effects
0.000
description
7
230000001988
toxicity
Effects
0.000
description
7
231100000419
toxicity
Toxicity
0.000
description
7
102100031126
6-phosphogluconolactonase
Human genes
0.000
description
6
108010029731
6-phosphogluconolactonase
Proteins
0.000
description
6
HBAQYPYDRFILMT-UHFFFAOYSA-N
8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one
Chemical class
C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O
HBAQYPYDRFILMT-UHFFFAOYSA-N
0.000
description
6
UHOVQNZJYSORNB-UHFFFAOYSA-N
Benzene
Chemical compound
C1=CC=CC=C1
UHOVQNZJYSORNB-UHFFFAOYSA-N
0.000
description
6
241000283707
Capra
Species
0.000
description
6
102000002004
Cytochrome P-450 Enzyme System
Human genes
0.000
description
6
108010015742
Cytochrome P-450 Enzyme System
Proteins
0.000
description
6
229940121710
HMGCoA reductase inhibitor
Drugs
0.000
description
6
MHAJPDPJQMAIIY-UHFFFAOYSA-N
Hydrogen peroxide
Chemical compound
OO
MHAJPDPJQMAIIY-UHFFFAOYSA-N
0.000
description
6
241000282567
Macaca fascicularis
Species
0.000
description
6
102100023175
NADP-dependent malic enzyme
Human genes
0.000
description
6
208000018737
Parkinson disease
Diseases
0.000
description
6
206010063837
Reperfusion injury
Diseases
0.000
description
6
HEMHJVSKTPXQMS-UHFFFAOYSA-M
Sodium hydroxide
Chemical compound
[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
6
102100031797
Sulfiredoxin-1
Human genes
0.000
description
6
101710091276
Sulfiredoxin-1
Proteins
0.000
description
6
YXFVVABEGXRONW-UHFFFAOYSA-N
Toluene
Chemical compound
CC1=CC=CC=C1
YXFVVABEGXRONW-UHFFFAOYSA-N
0.000
description
6
230000002411
adverse
Effects
0.000
description
6
238000010171
animal model
Methods
0.000
description
6
230000003110
anti-inflammatory effect
Effects
0.000
description
6
230000007423
decrease
Effects
0.000
description
6
229960004679
doxorubicin
Drugs
0.000
description
6
230000002526
effect on cardiovascular system
Effects
0.000
description
6
239000012091
fetal bovine serum
Substances
0.000
description
6
108010002929
galactose-6-phosphate dehydrogenase
Proteins
0.000
description
6
210000003494
hepatocyte
Anatomy
0.000
description
6
238000011534
incubation
Methods
0.000
description
6
239000003112
inhibitor
Substances
0.000
description
6
210000001503
joint
Anatomy
0.000
description
6
238000001294
liquid chromatography-tandem mass spectrometry
Methods
0.000
description
6
108090000286
malate dehydrogenase (decarboxylating)
Proteins
0.000
description
6
239000012528
membrane
Substances
0.000
description
6
230000004060
metabolic process
Effects
0.000
description
6
210000001589
microsome
Anatomy
0.000
description
6
238000012544
monitoring process
Methods
0.000
description
6
230000001105
regulatory effect
Effects
0.000
description
6
238000010839
reverse transcription
Methods
0.000
description
6
230000011664
signaling
Effects
0.000
description
6
239000011780
sodium chloride
Substances
0.000
description
6
238000010186
staining
Methods
0.000
description
6
201000000596
systemic lupus erythematosus
Diseases
0.000
description
6
238000013518
transcription
Methods
0.000
description
6
230000035897
transcription
Effects
0.000
description
6
VHYFNPMBLIVWCW-UHFFFAOYSA-N
4-Dimethylaminopyridine
Chemical compound
CN(C)C1=CC=NC=C1
VHYFNPMBLIVWCW-UHFFFAOYSA-N
0.000
description
5
102000004567
6-phosphogluconate dehydrogenase
Human genes
0.000
description
5
108020001657
6-phosphogluconate dehydrogenase
Proteins
0.000
description
5
238000011725
BALB/c mouse
Methods
0.000
description
5
OKTJSMMVPCPJKN-UHFFFAOYSA-N
Carbon
Chemical compound
[C]
OKTJSMMVPCPJKN-UHFFFAOYSA-N
0.000
description
5
206010019280
Heart failures
Diseases
0.000
description
5
101001047090
Homo sapiens Potassium voltage-gated channel subfamily H member 2
Proteins
0.000
description
5
108010074328
Interferon-gamma
Proteins
0.000
description
5
108020000284
NAD(P)H dehydrogenase (quinone)
Proteins
0.000
description
5
108010058846
Ovalbumin
Proteins
0.000
description
5
102100022807
Potassium voltage-gated channel subfamily H member 2
Human genes
0.000
description
5
241000288906
Primates
Species
0.000
description
5
208000006011
Stroke
Diseases
0.000
description
5
239000006180
TBST buffer
Substances
0.000
description
5
102000007591
Tartrate-Resistant Acid Phosphatase
Human genes
0.000
description
5
108010032050
Tartrate-Resistant Acid Phosphatase
Proteins
0.000
description
5
102000014701
Transketolase
Human genes
0.000
description
5
108010043652
Transketolase
Proteins
0.000
description
5
239000002253
acid
Substances
0.000
description
5
206010002026
amyotrophic lateral sclerosis
Diseases
0.000
description
5
238000004458
analytical method
Methods
0.000
description
5
230000006907
apoptotic process
Effects
0.000
description
5
210000003719
b-lymphocyte
Anatomy
0.000
description
5
239000003153
chemical reaction reagent
Substances
0.000
description
5
208000037976
chronic inflammation
Diseases
0.000
description
5
229940125782
compound 2
Drugs
0.000
description
5
230000001472
cytotoxic effect
Effects
0.000
description
5
210000004443
dendritic cell
Anatomy
0.000
description
5
230000001419
dependent effect
Effects
0.000
description
5
238000005516
engineering process
Methods
0.000
description
5
201000001421
hyperglycemia
Diseases
0.000
description
5
238000009169
immunotherapy
Methods
0.000
description
5
230000004968
inflammatory condition
Effects
0.000
description
5
208000028867
ischemia
Diseases
0.000
description
5
208000012947
ischemia reperfusion injury
Diseases
0.000
description
5
230000001404
mediated effect
Effects
0.000
description
5
210000004379
membrane
Anatomy
0.000
description
5
210000004985
myeloid-derived suppressor cell
Anatomy
0.000
description
5
VLKZOEOYAKHREP-UHFFFAOYSA-N
n-Hexane
Chemical compound
CCCCCC
VLKZOEOYAKHREP-UHFFFAOYSA-N
0.000
description
5
229940092253
ovalbumin
Drugs
0.000
description
5
CMFNMSMUKZHDEY-UHFFFAOYSA-M
peroxynitrite
Chemical compound
[O-]ON=O
CMFNMSMUKZHDEY-UHFFFAOYSA-M
0.000
description
5
230000026731
phosphorylation
Effects
0.000
description
5
238000006366
phosphorylation reaction
Methods
0.000
description
5
239000000047
product
Substances
0.000
description
5
230000000750
progressive effect
Effects
0.000
description
5
230000002685
pulmonary effect
Effects
0.000
description
5
210000000278
spinal cord
Anatomy
0.000
description
5
239000007858
starting material
Substances
0.000
description
5
239000000126
substance
Substances
0.000
description
5
230000001629
suppression
Effects
0.000
description
5
238000001356
surgical procedure
Methods
0.000
description
5
102000014898
transaminase activity proteins
Human genes
0.000
description
5
MIJYXULNPSFWEK-GTOFXWBISA-N
3beta-hydroxyolean-12-en-28-oic acid
Chemical compound
C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C
MIJYXULNPSFWEK-GTOFXWBISA-N
0.000
description
4
SHGAZHPCJJPHSC-ZVCIMWCZSA-N
9-cis-retinoic acid
Chemical compound
OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C
SHGAZHPCJJPHSC-ZVCIMWCZSA-N
0.000
description
4
208000009304
Acute Kidney Injury
Diseases
0.000
description
4
102100036475
Alanine aminotransferase 1
Human genes
0.000
description
4
TXGZJQLMVSIZEI-UQMAOPSPSA-N
Bardoxolone
Chemical compound
C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C
TXGZJQLMVSIZEI-UQMAOPSPSA-N
0.000
description
4
102000004506
Blood Proteins
Human genes
0.000
description
4
108010017384
Blood Proteins
Proteins
0.000
description
4
238000011740
C57BL/6 mouse
Methods
0.000
description
4
102100037904
CD9 antigen
Human genes
0.000
description
4
241000699800
Cricetinae
Species
0.000
description
4
CMSMOCZEIVJLDB-UHFFFAOYSA-N
Cyclophosphamide
Chemical compound
ClCCN(CCCl)P1(=O)NCCCO1
CMSMOCZEIVJLDB-UHFFFAOYSA-N
0.000
description
4
108010081668
Cytochrome P-450 CYP3A
Proteins
0.000
description
4
206010012735
Diarrhoea
Diseases
0.000
description
4
JKLISIRFYWXLQG-UHFFFAOYSA-N
Epioleonolsaeure
Natural products
C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C
JKLISIRFYWXLQG-UHFFFAOYSA-N
0.000
description
4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound
CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
4
206010016654
Fibrosis
Diseases
0.000
description
4
102100033398
Glutamate-cysteine ligase regulatory subunit
Human genes
0.000
description
4
101000870644
Homo sapiens Glutamate-cysteine ligase regulatory subunit
Proteins
0.000
description
4
PMMYEEVYMWASQN-DMTCNVIQSA-N
Hydroxyproline
Chemical compound
O[C@H]1CN[C@H](C(O)=O)C1
PMMYEEVYMWASQN-DMTCNVIQSA-N
0.000
description
4
206010022489
Insulin Resistance
Diseases
0.000
description
4
208000036110
Neuroinflammatory disease
Diseases
0.000
description
4
YBRJHZPWOMJYKQ-UHFFFAOYSA-N
Oleanolic acid
Natural products
CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O
YBRJHZPWOMJYKQ-UHFFFAOYSA-N
0.000
description
4
MIJYXULNPSFWEK-UHFFFAOYSA-N
Oleanolinsaeure
Natural products
C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C
MIJYXULNPSFWEK-UHFFFAOYSA-N
0.000
description
4
102000014128
RANK Ligand
Human genes
0.000
description
4
108010025832
RANK Ligand
Proteins
0.000
description
4
208000033626
Renal failure acute
Diseases
0.000
description
4
101001109714
Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1
Proteins
0.000
description
4
102000004282
Ribosomal protein S9
Human genes
0.000
description
4
108090000878
Ribosomal protein S9
Proteins
0.000
description
4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
Silicium dioxide
Chemical compound
O=[Si]=O
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
0.000
description
4
OUUQCZGPVNCOIJ-UHFFFAOYSA-M
Superoxide
Chemical compound
[O-][O]
OUUQCZGPVNCOIJ-UHFFFAOYSA-M
0.000
description
4
NKANXQFJJICGDU-QPLCGJKRSA-N
Tamoxifen
Chemical compound
C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1
NKANXQFJJICGDU-QPLCGJKRSA-N
0.000
description
4
206010052779
Transplant rejections
Diseases
0.000
description
4
206010067584
Type 1 diabetes mellitus
Diseases
0.000
description
4
JXLYSJRDGCGARV-WWYNWVTFSA-N
Vinblastine
Natural products
O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C
JXLYSJRDGCGARV-WWYNWVTFSA-N
0.000
description
4
RJURFGZVJUQBHK-UHFFFAOYSA-N
actinomycin D
Natural products
CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21
RJURFGZVJUQBHK-UHFFFAOYSA-N
0.000
description
4
201000011040
acute kidney failure
Diseases
0.000
description
4
229960001445
alitretinoin
Drugs
0.000
description
4
SHGAZHPCJJPHSC-YCNIQYBTSA-N
all-trans-retinoic acid
Chemical compound
OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
SHGAZHPCJJPHSC-YCNIQYBTSA-N
0.000
description
4
239000000090
biomarker
Substances
0.000
description
4
125000003178
carboxy group
Chemical group
[H]OC(*)=O
0.000
description
4
230000003833
cell viability
Effects
0.000
description
4
230000006020
chronic inflammation
Effects
0.000
description
4
229960004316
cisplatin
Drugs
0.000
description
4
DQLATGHUWYMOKM-UHFFFAOYSA-L
cisplatin
Chemical compound
N[Pt](N)(Cl)Cl
DQLATGHUWYMOKM-UHFFFAOYSA-L
0.000
description
4
229940125904
compound 1
Drugs
0.000
description
4
238000002425
crystallisation
Methods
0.000
description
4
230000008025
crystallization
Effects
0.000
description
4
229960004397
cyclophosphamide
Drugs
0.000
description
4
231100000433
cytotoxic
Toxicity
0.000
description
4
230000008021
deposition
Effects
0.000
description
4
238000001938
differential scanning calorimetry curve
Methods
0.000
description
4
PMMYEEVYMWASQN-UHFFFAOYSA-N
dl-hydroxyproline
Natural products
OC1C[NH2+]C(C([O-])=O)C1
PMMYEEVYMWASQN-UHFFFAOYSA-N
0.000
description
4
230000008482
dysregulation
Effects
0.000
description
4
206010015037
epilepsy
Diseases
0.000
description
4
235000019439
ethyl acetate
Nutrition
0.000
description
4
229960005420
etoposide
Drugs
0.000
description
4
VJJPUSNTGOMMGY-MRVIYFEKSA-N
etoposide
Chemical compound
COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1
VJJPUSNTGOMMGY-MRVIYFEKSA-N
0.000
description
4
210000002950
fibroblast
Anatomy
0.000
description
4
230000004761
fibrosis
Effects
0.000
description
4
239000012530
fluid
Substances
0.000
description
4
210000001280
germinal center
Anatomy
0.000
description
4
238000010438
heat treatment
Methods
0.000
description
4
238000000589
high-performance liquid chromatography-mass spectrometry
Methods
0.000
description
4
239000002471
hydroxymethylglutaryl coenzyme A reductase inhibitor
Substances
0.000
description
4
229960002591
hydroxyproline
Drugs
0.000
description
4
239000004615
ingredient
Substances
0.000
description
4
230000003834
intracellular effect
Effects
0.000
description
4
210000000265
leukocyte
Anatomy
0.000
description
4
238000010172
mouse model
Methods
0.000
description
4
108010066052
multidrug resistance-associated protein 1
Proteins
0.000
description
4
208000010125
myocardial infarction
Diseases
0.000
description
4
230000003188
neurobehavioral effect
Effects
0.000
description
4
230000003959
neuroinflammation
Effects
0.000
description
4
229940100243
oleanolic acid
Drugs
0.000
description
4
210000002997
osteoclast
Anatomy
0.000
description
4
230000008506
pathogenesis
Effects
0.000
description
4
230000000144
pharmacologic effect
Effects
0.000
description
4
239000013612
plasmid
Substances
0.000
description
4
230000003389
potentiating effect
Effects
0.000
description
4
239000000843
powder
Substances
0.000
description
4
AQHHHDLHHXJYJD-UHFFFAOYSA-N
propranolol
Chemical compound
C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1
AQHHHDLHHXJYJD-UHFFFAOYSA-N
0.000
description
4
HZLWUYJLOIAQFC-UHFFFAOYSA-N
prosapogenin PS-A
Natural products
C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O
HZLWUYJLOIAQFC-UHFFFAOYSA-N
0.000
description
4
150000003180
prostaglandins
Chemical class
0.000
description
4
230000019491
signal transduction
Effects
0.000
description
4
239000000741
silica gel
Substances
0.000
description
4
229910002027
silica gel
Inorganic materials
0.000
description
4
UCSJYZPVAKXKNQ-HZYVHMACSA-N
streptomycin
Chemical compound
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O
UCSJYZPVAKXKNQ-HZYVHMACSA-N
0.000
description
4
229960005322
streptomycin
Drugs
0.000
description
4
239000000758
substrate
Substances
0.000
description
4
229940124597
therapeutic agent
Drugs
0.000
description
4
230000000451
tissue damage
Effects
0.000
description
4
231100000827
tissue damage
Toxicity
0.000
description
4
FGMPLJWBKKVCDB-UHFFFAOYSA-N
trans-L-hydroxy-proline
Natural products
ON1CCCC1C(O)=O
FGMPLJWBKKVCDB-UHFFFAOYSA-N
0.000
description
4
230000007306
turnover
Effects
0.000
description
4
229960003048
vinblastine
Drugs
0.000
description
4
JXLYSJRDGCGARV-XQKSVPLYSA-N
vincaleukoblastine
Chemical compound
C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21
JXLYSJRDGCGARV-XQKSVPLYSA-N
0.000
description
4
229960002066
vinorelbine
Drugs
0.000
description
4
GBABOYUKABKIAF-GHYRFKGUSA-N
vinorelbine
Chemical compound
C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC
GBABOYUKABKIAF-GHYRFKGUSA-N
0.000
description
4
AOJJSUZBOXZQNB-VTZDEGQISA-N
4'-epidoxorubicin
Chemical compound
O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
AOJJSUZBOXZQNB-VTZDEGQISA-N
0.000
description
3
QTBSBXVTEAMEQO-UHFFFAOYSA-N
Acetic acid
Chemical compound
CC(O)=O
QTBSBXVTEAMEQO-UHFFFAOYSA-N
0.000
description
3
102100033814
Alanine aminotransferase 2
Human genes
0.000
description
3
206010003253
Arthritis enteropathic
Diseases
0.000
description
3
206010003267
Arthritis reactive
Diseases
0.000
description
3
102100034193
Aspartate aminotransferase, mitochondrial
Human genes
0.000
description
3
208000037260
Atherosclerotic Plaque
Diseases
0.000
description
3
206010003805
Autism
Diseases
0.000
description
3
208000020706
Autistic disease
Diseases
0.000
description
3
208000035143
Bacterial infection
Diseases
0.000
description
3
BPYKTIZUTYGOLE-IFADSCNNSA-N
Bilirubin
Chemical compound
N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1
BPYKTIZUTYGOLE-IFADSCNNSA-N
0.000
description
3
208000020925
Bipolar disease
Diseases
0.000
description
3
102100032367
C-C motif chemokine 5
Human genes
0.000
description
3
102100025277
C-X-C motif chemokine 13
Human genes
0.000
description
3
GAGWJHPBXLXJQN-UORFTKCHSA-N
Capecitabine
Chemical compound
C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1
GAGWJHPBXLXJQN-UORFTKCHSA-N
0.000
description
3
GAGWJHPBXLXJQN-UHFFFAOYSA-N
Capecitabine
Natural products
C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1
GAGWJHPBXLXJQN-UHFFFAOYSA-N
0.000
description
3
UGFAIRIUMAVXCW-UHFFFAOYSA-N
Carbon monoxide
Chemical compound
[O+]#[C-]
UGFAIRIUMAVXCW-UHFFFAOYSA-N
0.000
description
3
108010055166
Chemokine CCL5
Proteins
0.000
description
3
208000000094
Chronic Pain
Diseases
0.000
description
3
108010035532
Collagen
Proteins
0.000
description
3
102000008186
Collagen
Human genes
0.000
description
3
208000035473
Communicable disease
Diseases
0.000
description
3
108010074922
Cytochrome P-450 CYP1A2
Proteins
0.000
description
3
108010020070
Cytochrome P-450 CYP2B6
Proteins
0.000
description
3
102000009666
Cytochrome P-450 CYP2B6
Human genes
0.000
description
3
102100039205
Cytochrome P450 3A4
Human genes
0.000
description
3
102100036279
DNA (cytosine-5)-methyltransferase 1
Human genes
0.000
description
3
QOSSAOTZNIDXMA-UHFFFAOYSA-N
Dicylcohexylcarbodiimide
Chemical compound
C1CCCCC1N=C=NC1CCCCC1
QOSSAOTZNIDXMA-UHFFFAOYSA-N
0.000
description
3
239000006144
Dulbecco’s modified Eagle's medium
Substances
0.000
description
3
HTIJFSOGRVMCQR-UHFFFAOYSA-N
Epirubicin
Natural products
COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO
HTIJFSOGRVMCQR-UHFFFAOYSA-N
0.000
description
3
206010018364
Glomerulonephritis
Diseases
0.000
description
3
102100036442
Glutathione reductase, mitochondrial
Human genes
0.000
description
3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
Glycerine
Chemical compound
OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
3
101000858064
Homo sapiens C-X-C motif chemokine 13
Proteins
0.000
description
3
UFHFLCQGNIYNRP-UHFFFAOYSA-N
Hydrogen
Chemical compound
[H][H]
UFHFLCQGNIYNRP-UHFFFAOYSA-N
0.000
description
3
102100034343
Integrase
Human genes
0.000
description
3
102100037850
Interferon gamma
Human genes
0.000
description
3
102000014158
Interleukin-12 Subunit p40
Human genes
0.000
description
3
108010011429
Interleukin-12 Subunit p40
Proteins
0.000
description
3
FBOZXECLQNJBKD-ZDUSSCGKSA-N
L-methotrexate
Chemical compound
C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1
FBOZXECLQNJBKD-ZDUSSCGKSA-N
0.000
description
3
208000001145
Metabolic Syndrome
Diseases
0.000
description
3
OKKJLVBELUTLKV-UHFFFAOYSA-N
Methanol
Chemical compound
OC
OKKJLVBELUTLKV-UHFFFAOYSA-N
0.000
description
3
LRHPLDYGYMQRHN-UHFFFAOYSA-N
N-Butanol
Chemical compound
CCCCO
LRHPLDYGYMQRHN-UHFFFAOYSA-N
0.000
description
3
208000008589
Obesity
Diseases
0.000
description
3
241000283973
Oryctolagus cuniculus
Species
0.000
description
3
MUBZPKHOEPUJKR-UHFFFAOYSA-N
Oxalic acid
Chemical compound
OC(=O)C(O)=O
MUBZPKHOEPUJKR-UHFFFAOYSA-N
0.000
description
3
229910019142
PO4
Inorganic materials
0.000
description
3
241000009328
Perro
Species
0.000
description
3
KWYUFKZDYYNOTN-UHFFFAOYSA-M
Potassium hydroxide
Chemical compound
[OH-].[K+]
KWYUFKZDYYNOTN-UHFFFAOYSA-M
0.000
description
3
OFOBLEOULBTSOW-UHFFFAOYSA-N
Propanedioic acid
Natural products
OC(=O)CC(O)=O
OFOBLEOULBTSOW-UHFFFAOYSA-N
0.000
description
3
108010092799
RNA-directed DNA polymerase
Proteins
0.000
description
3
238000011529
RT qPCR
Methods
0.000
description
3
206010060872
Transplant failure
Diseases
0.000
description
3
238000002441
X-ray diffraction
Methods
0.000
description
3
201000000690
abdominal obesity-metabolic syndrome
Diseases
0.000
description
3
230000009471
action
Effects
0.000
description
3
230000003321
amplification
Effects
0.000
description
3
230000001028
anti-proliverative effect
Effects
0.000
description
3
238000003149
assay kit
Methods
0.000
description
3
VSRXQHXAPYXROS-UHFFFAOYSA-N
azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
Chemical compound
[NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1
VSRXQHXAPYXROS-UHFFFAOYSA-N
0.000
description
3
208000022362
bacterial infectious disease
Diseases
0.000
description
3
230000006399
behavior
Effects
0.000
description
3
230000009286
beneficial effect
Effects
0.000
description
3
229960000397
bevacizumab
Drugs
0.000
description
3
230000003115
biocidal effect
Effects
0.000
description
3
230000008499
blood brain barrier function
Effects
0.000
description
3
230000017531
blood circulation
Effects
0.000
description
3
210000001218
blood-brain barrier
Anatomy
0.000
description
3
230000036760
body temperature
Effects
0.000
description
3
210000000424
bronchial epithelial cell
Anatomy
0.000
description
3
238000004364
calculation method
Methods
0.000
description
3
239000012830
cancer therapeutic
Substances
0.000
description
3
229960004117
capecitabine
Drugs
0.000
description
3
229910002091
carbon monoxide
Inorganic materials
0.000
description
3
229960004562
carboplatin
Drugs
0.000
description
3
230000004663
cell proliferation
Effects
0.000
description
3
230000005754
cellular signaling
Effects
0.000
description
3
229960005395
cetuximab
Drugs
0.000
description
3
KRKNYBCHXYNGOX-UHFFFAOYSA-N
citric acid
Chemical compound
OC(=O)CC(O)(C(O)=O)CC(O)=O
KRKNYBCHXYNGOX-UHFFFAOYSA-N
0.000
description
3
229920001436
collagen
Polymers
0.000
description
3
230000000052
comparative effect
Effects
0.000
description
3
239000002299
complementary DNA
Substances
0.000
description
3
229940126214
compound 3
Drugs
0.000
description
3
238000002247
constant time method
Methods
0.000
description
3
208000029078
coronary artery disease
Diseases
0.000
description
3
230000000875
corresponding effect
Effects
0.000
description
3
230000003247
decreasing effect
Effects
0.000
description
3
UREBDLICKHMUKA-CXSFZGCWSA-N
dexamethasone
Chemical compound
C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O
UREBDLICKHMUKA-CXSFZGCWSA-N
0.000
description
3
230000004069
differentiation
Effects
0.000
description
3
XBDQKXXYIPTUBI-UHFFFAOYSA-N
dimethylselenoniopropionate
Natural products
CCC(O)=O
XBDQKXXYIPTUBI-UHFFFAOYSA-N
0.000
description
3
MKRTXPORKIRPDG-UHFFFAOYSA-N
diphenylphosphoryl azide
Chemical compound
C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1
MKRTXPORKIRPDG-UHFFFAOYSA-N
0.000
description
3
230000002255
enzymatic effect
Effects
0.000
description
3
229960001904
epirubicin
Drugs
0.000
description
3
150000002148
esters
Chemical class
0.000
description
3
239000006260
foam
Substances
0.000
description
3
235000013305
food
Nutrition
0.000
description
3
239000000499
gel
Substances
0.000
description
3
229960005277
gemcitabine
Drugs
0.000
description
3
SDUQYLNIPVEERB-QPPQHZFASA-N
gemcitabine
Chemical compound
O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1
SDUQYLNIPVEERB-QPPQHZFASA-N
0.000
description
3
230000009477
glass transition
Effects
0.000
description
3
230000002414
glycolytic effect
Effects
0.000
description
3
229910052739
hydrogen
Inorganic materials
0.000
description
3
239000001257
hydrogen
Substances
0.000
description
3
HOMGKSMUEGBAAB-UHFFFAOYSA-N
ifosfamide
Chemical compound
ClCCNP1(=O)OCCCN1CCCl
HOMGKSMUEGBAAB-UHFFFAOYSA-N
0.000
description
3
229960001101
ifosfamide
Drugs
0.000
description
3
230000001506
immunosuppresive effect
Effects
0.000
description
3
230000001976
improved effect
Effects
0.000
description
3
230000006872
improvement
Effects
0.000
description
3
230000001939
inductive effect
Effects
0.000
description
3
229960004768
irinotecan
Drugs
0.000
description
3
UWKQSNNFCGGAFS-XIFFEERXSA-N
irinotecan
Chemical compound
C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1
UWKQSNNFCGGAFS-XIFFEERXSA-N
0.000
description
3
SUMDYPCJJOFFON-UHFFFAOYSA-N
isethionic acid
Chemical compound
OCCS(O)(=O)=O
SUMDYPCJJOFFON-UHFFFAOYSA-N
0.000
description
3
239000002502
liposome
Substances
0.000
description
3
210000001853
liver microsome
Anatomy
0.000
description
3
238000003468
luciferase reporter gene assay
Methods
0.000
description
3
239000006166
lysate
Substances
0.000
description
3
230000003211
malignant effect
Effects
0.000
description
3
SGDBTWWWUNNDEQ-LBPRGKRZSA-N
melphalan
Chemical compound
OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N
0.000
description
3
229960001924
melphalan
Drugs
0.000
description
3
239000000155
melt
Substances
0.000
description
3
239000002207
metabolite
Substances
0.000
description
3
229960000485
methotrexate
Drugs
0.000
description
3
210000000274
microglia
Anatomy
0.000
description
3
KKZJGLLVHKMTCM-UHFFFAOYSA-N
mitoxantrone
Chemical compound
O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO
KKZJGLLVHKMTCM-UHFFFAOYSA-N
0.000
description
3
229960001156
mitoxantrone
Drugs
0.000
description
3
239000003607
modifier
Substances
0.000
description
3
210000000663
muscle cell
Anatomy
0.000
description
3
238000003199
nucleic acid amplification method
Methods
0.000
description
3
235000020824
obesity
Nutrition
0.000
description
3
DWAFYCQODLXJNR-BNTLRKBRSA-L
oxaliplatin
Chemical compound
O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1
DWAFYCQODLXJNR-BNTLRKBRSA-L
0.000
description
3
229960001756
oxaliplatin
Drugs
0.000
description
3
230000002093
peripheral effect
Effects
0.000
description
3
230000003285
pharmacodynamic effect
Effects
0.000
description
3
239000002831
pharmacologic agent
Substances
0.000
description
3
235000021317
phosphate
Nutrition
0.000
description
3
230000003334
potential effect
Effects
0.000
description
3
238000001556
precipitation
Methods
0.000
description
3
230000002035
prolonged effect
Effects
0.000
description
3
230000001681
protective effect
Effects
0.000
description
3
208000020016
psychiatric disease
Diseases
0.000
description
3
208000002574
reactive arthritis
Diseases
0.000
description
3
239000003642
reactive oxygen metabolite
Substances
0.000
description
3
238000003753
real-time PCR
Methods
0.000
description
3
210000001525
retina
Anatomy
0.000
description
3
239000006228
supernatant
Substances
0.000
description
3
239000003826
tablet
Substances
0.000
description
3
230000008685
targeting
Effects
0.000
description
3
229960000303
topotecan
Drugs
0.000
description
3
UCFGDBYHRUNTLO-QHCPKHFHSA-N
topotecan
Chemical compound
C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1
UCFGDBYHRUNTLO-QHCPKHFHSA-N
0.000
description
3
231100000331
toxic
Toxicity
0.000
description
3
230000002588
toxic effect
Effects
0.000
description
3
230000002103
transcriptional effect
Effects
0.000
description
3
230000009466
transformation
Effects
0.000
description
3
238000002054
transplantation
Methods
0.000
description
3
229960000575
trastuzumab
Drugs
0.000
description
3
230000008733
trauma
Effects
0.000
description
3
150000003648
triterpenes
Chemical class
0.000
description
3
230000004614
tumor growth
Effects
0.000
description
3
230000024883
vasodilation
Effects
0.000
description
3
CEMAWMOMDPGJMB-UHFFFAOYSA-N
(+-)-Oxprenolol
Chemical compound
CC(C)NCC(O)COC1=CC=CC=C1OCC=C
CEMAWMOMDPGJMB-UHFFFAOYSA-N
0.000
description
2
YKFCISHFRZHKHY-NGQGLHOPSA-N
(2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate
Chemical compound
O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1
YKFCISHFRZHKHY-NGQGLHOPSA-N
0.000
description
2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M
(3R,5S)-fluvastatin sodium
Chemical compound
[Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M
0.000
description
2
OMJKFYKNWZZKTK-POHAHGRESA-N
(5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
Chemical compound
CN(C)N\N=C1/N=CN=C1C(N)=O
OMJKFYKNWZZKTK-POHAHGRESA-N
0.000
description
2
METKIMKYRPQLGS-GFCCVEGCSA-N
(R)-atenolol
Chemical compound
CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1
METKIMKYRPQLGS-GFCCVEGCSA-N
0.000
description
2
PVHUJELLJLJGLN-INIZCTEOSA-N
(S)-nitrendipine
Chemical compound
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1
PVHUJELLJLJGLN-INIZCTEOSA-N
0.000
description
2
TWBNMYSKRDRHAT-RCWTXCDDSA-N
(S)-timolol hemihydrate
Chemical compound
O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
TWBNMYSKRDRHAT-RCWTXCDDSA-N
0.000
description
2
238000005160
1H NMR spectroscopy
Methods
0.000
description
2
HZAXFHJVJLSVMW-UHFFFAOYSA-N
2-Aminoethan-1-ol
Chemical compound
NCCO
HZAXFHJVJLSVMW-UHFFFAOYSA-N
0.000
description
2
FBMYKMYQHCBIGU-UHFFFAOYSA-N
2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
Chemical compound
C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N
FBMYKMYQHCBIGU-UHFFFAOYSA-N
0.000
description
2
RTQWWZBSTRGEAV-PKHIMPSTSA-N
2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid
Chemical compound
CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1
RTQWWZBSTRGEAV-PKHIMPSTSA-N
0.000
description
2
SGUAFYQXFOLMHL-UHFFFAOYSA-N
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
Chemical compound
C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1
SGUAFYQXFOLMHL-UHFFFAOYSA-N
0.000
description
2
NDMPLJNOPCLANR-UHFFFAOYSA-N
3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester
Natural products
C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12
NDMPLJNOPCLANR-UHFFFAOYSA-N
0.000
description
2
JXZZEXZZKAWDSP-UHFFFAOYSA-N
3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole
Chemical compound
C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1
JXZZEXZZKAWDSP-UHFFFAOYSA-N
0.000
description
2
UIAGMCDKSXEBJQ-IBGZPJMESA-N
3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Chemical compound
COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1
UIAGMCDKSXEBJQ-IBGZPJMESA-N
0.000
description
2
XMIIGOLPHOKFCH-UHFFFAOYSA-N
3-phenylpropionic acid
Chemical compound
OC(=O)CCC1=CC=CC=C1
XMIIGOLPHOKFCH-UHFFFAOYSA-N
0.000
description
2
XXJWYDDUDKYVKI-UHFFFAOYSA-N
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline
Chemical compound
COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1
XXJWYDDUDKYVKI-UHFFFAOYSA-N
0.000
description
2
229960000549
4-dimethylaminophenol
Drugs
0.000
description
2
XAUDJQYHKZQPEU-KVQBGUIXSA-N
5-aza-2'-deoxycytidine
Chemical compound
O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1
XAUDJQYHKZQPEU-KVQBGUIXSA-N
0.000
description
2
NMUSYJAQQFHJEW-KVTDHHQDSA-N
5-azacytidine
Chemical compound
O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1
NMUSYJAQQFHJEW-KVTDHHQDSA-N
0.000
description
2
RZTAMFZIAATZDJ-HNNXBMFYSA-N
5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Chemical compound
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl
RZTAMFZIAATZDJ-HNNXBMFYSA-N
0.000
description
2
WYWHKKSPHMUBEB-UHFFFAOYSA-N
6-Mercaptoguanine
Natural products
N1C(N)=NC(=S)C2=C1N=CN2
WYWHKKSPHMUBEB-UHFFFAOYSA-N
0.000
description
2
STQGQHZAVUOBTE-UHFFFAOYSA-N
7-Cyan-hept-2t-en-4,6-diinsaeure
Natural products
C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1
STQGQHZAVUOBTE-UHFFFAOYSA-N
0.000
description
2
208000004998
Abdominal Pain
Diseases
0.000
description
2
RZVAJINKPMORJF-UHFFFAOYSA-N
Acetaminophen
Chemical compound
CC(=O)NC1=CC=C(O)C=C1
RZVAJINKPMORJF-UHFFFAOYSA-N
0.000
description
2
102000007469
Actins
Human genes
0.000
description
2
108010085238
Actins
Proteins
0.000
description
2
101710096214
Alanine aminotransferase 1
Proteins
0.000
description
2
101710096000
Alanine aminotransferase 2
Proteins
0.000
description
2
108010082126
Alanine transaminase
Proteins
0.000
description
2
102000004452
Arginase
Human genes
0.000
description
2
108700024123
Arginases
Proteins
0.000
description
2
102100036608
Aspartate aminotransferase, cytoplasmic
Human genes
0.000
description
2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Aspirin
Chemical compound
CC(=O)OC1=CC=CC=C1C(O)=O
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
0.000
description
2
IJGRMHOSHXDMSA-UHFFFAOYSA-N
Atomic nitrogen
Chemical compound
N#N
IJGRMHOSHXDMSA-UHFFFAOYSA-N
0.000
description
2
XUKUURHRXDUEBC-KAYWLYCHSA-N
Atorvastatin
Chemical compound
C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1
XUKUURHRXDUEBC-KAYWLYCHSA-N
0.000
description
2
XUKUURHRXDUEBC-UHFFFAOYSA-N
Atorvastatin
Natural products
C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1
XUKUURHRXDUEBC-UHFFFAOYSA-N
0.000
description
2
208000006096
Attention Deficit Disorder with Hyperactivity
Diseases
0.000
description
2
239000005711
Benzoic acid
Substances
0.000
description
2
241000283690
Bos taurus
Species
0.000
description
2
108091003079
Bovine Serum Albumin
Proteins
0.000
description
2
COVZYZSDYWQREU-UHFFFAOYSA-N
Busulfan
Chemical compound
CS(=O)(=O)OCCCCOS(C)(=O)=O
COVZYZSDYWQREU-UHFFFAOYSA-N
0.000
description
2
LDGIHZJOIQSHPB-UHFFFAOYSA-N
CD437
Chemical compound
C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O
LDGIHZJOIQSHPB-UHFFFAOYSA-N
0.000
description
2
FVLVBPDQNARYJU-XAHDHGMMSA-N
C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O
Chemical compound
C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O
FVLVBPDQNARYJU-XAHDHGMMSA-N
0.000
description
2
229940127291
Calcium channel antagonist
Drugs
0.000
description
2
206010007559
Cardiac failure congestive
Diseases
0.000
description
2
DLGOEMSEDOSKAD-UHFFFAOYSA-N
Carmustine
Chemical compound
ClCCNC(=O)N(N=O)CCCl
DLGOEMSEDOSKAD-UHFFFAOYSA-N
0.000
description
2
241000700199
Cavia porcellus
Species
0.000
description
2
108091006146
Channels
Proteins
0.000
description
2
108010012236
Chemokines
Proteins
0.000
description
2
102000019034
Chemokines
Human genes
0.000
description
2
GJSURZIOUXUGAL-UHFFFAOYSA-N
Clonidine
Chemical compound
ClC1=CC=CC(Cl)=C1NC1=NCCN1
GJSURZIOUXUGAL-UHFFFAOYSA-N
0.000
description
2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
Cytarabine
Chemical compound
O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
0.000
description
2
102100026533
Cytochrome P450 1A2
Human genes
0.000
description
2
RGHNJXZEOKUKBD-SQOUGZDYSA-N
D-gluconic acid
Chemical compound
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O
RGHNJXZEOKUKBD-SQOUGZDYSA-N
0.000
description
2
108010092160
Dactinomycin
Proteins
0.000
description
2
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
Dasatinib
Chemical compound
C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
0.000
description
2
208000016192
Demyelinating disease
Diseases
0.000
description
2
206010012305
Demyelination
Diseases
0.000
description
2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N
Dimethyl sulfoxide
Chemical compound
[2H]C([2H])([2H])S(=O)C([2H])([2H])[2H]
IAZDPXIOMUYVGZ-WFGJKAKNSA-N
0.000
description
2
OFDNQWIFNXBECV-UHFFFAOYSA-N
Dolastatin 10
Natural products
CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1
OFDNQWIFNXBECV-UHFFFAOYSA-N
0.000
description
2
ITIONVBQFUNVJV-UHFFFAOYSA-N
Etomidoline
Chemical compound
C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1
ITIONVBQFUNVJV-UHFFFAOYSA-N
0.000
description
2
241000282326
Felis catus
Species
0.000
description
2
VZCYOOQTPOCHFL-OWOJBTEDSA-N
Fumaric acid
Chemical compound
OC(=O)\C=C\C(O)=O
VZCYOOQTPOCHFL-OWOJBTEDSA-N
0.000
description
2
101150100264
GOT2 gene
Proteins
0.000
description
2
108010081687
Glutamate-cysteine ligase
Proteins
0.000
description
2
108010063907
Glutathione Reductase
Proteins
0.000
description
2
108010070675
Glutathione transferase
Proteins
0.000
description
2
102000005720
Glutathione transferase
Human genes
0.000
description
2
AEMRFAOFKBGASW-UHFFFAOYSA-N
Glycolic acid
Chemical compound
OCC(O)=O
AEMRFAOFKBGASW-UHFFFAOYSA-N
0.000
description
2
108010023302
HDL Cholesterol
Proteins
0.000
description
2
206010019663
Hepatic failure
Diseases
0.000
description
2
101000799549
Homo sapiens Aspartate aminotransferase, mitochondrial
Proteins
0.000
description
2
101000973778
Homo sapiens NAD(P)H dehydrogenase [quinone] 1
Proteins
0.000
description
2
101000617830
Homo sapiens Sterol O-acyltransferase 1
Proteins
0.000
description
2
208000023105
Huntington disease
Diseases
0.000
description
2
VEXZGXHMUGYJMC-UHFFFAOYSA-N
Hydrochloric acid
Chemical compound
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-N
0.000
description
2
208000013016
Hypoglycemia
Diseases
0.000
description
2
XDXDZDZNSLXDNA-TZNDIEGXSA-N
Idarubicin
Chemical compound
C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1
XDXDZDZNSLXDNA-TZNDIEGXSA-N
0.000
description
2
XDXDZDZNSLXDNA-UHFFFAOYSA-N
Idarubicin
Natural products
C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1
XDXDZDZNSLXDNA-UHFFFAOYSA-N
0.000
description
2
102000008070
Interferon-gamma
Human genes
0.000
description
2
XEEYBQQBJWHFJM-UHFFFAOYSA-N
Iron
Chemical compound
[Fe]
XEEYBQQBJWHFJM-UHFFFAOYSA-N
0.000
description
2
SHGAZHPCJJPHSC-NUEINMDLSA-N
Isotretinoin
Chemical compound
OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C
SHGAZHPCJJPHSC-NUEINMDLSA-N
0.000
description
2
238000003109
Karl Fischer titration
Methods
0.000
description
2
AHLPHDHHMVZTML-BYPYZUCNSA-N
L-Ornithine
Chemical compound
NCCC[C@H](N)C(O)=O
AHLPHDHHMVZTML-BYPYZUCNSA-N
0.000
description
2
RHGKLRLOHDJJDR-BYPYZUCNSA-N
L-citrulline
Chemical compound
NC(=O)NCCC[C@H]([NH3+])C([O-])=O
RHGKLRLOHDJJDR-BYPYZUCNSA-N
0.000
description
2
239000005517
L01XE01 - Imatinib
Substances
0.000
description
2
239000005411
L01XE02 - Gefitinib
Substances
0.000
description
2
239000005551
L01XE03 - Erlotinib
Substances
0.000
description
2
239000002147
L01XE04 - Sunitinib
Substances
0.000
description
2
239000002067
L01XE06 - Dasatinib
Substances
0.000
description
2
239000002136
L01XE07 - Lapatinib
Substances
0.000
description
2
239000005536
L01XE08 - Nilotinib
Substances
0.000
description
2
239000002118
L01XE12 - Vandetanib
Substances
0.000
description
2
239000002145
L01XE14 - Bosutinib
Substances
0.000
description
2
241000254158
Lampyridae
Species
0.000
description
2
XNRVGTHNYCNCFF-UHFFFAOYSA-N
Lapatinib ditosylate monohydrate
Chemical compound
O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1
XNRVGTHNYCNCFF-UHFFFAOYSA-N
0.000
description
2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N
Lomustine
Chemical compound
ClCCN(N=O)C(=O)NC1CCCCC1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N
0.000
description
2
102000004083
Lymphotoxin-alpha
Human genes
0.000
description
2
108090000542
Lymphotoxin-alpha
Proteins
0.000
description
2
206010027476
Metastases
Diseases
0.000
description
2
AFVFQIVMOAPDHO-UHFFFAOYSA-N
Methanesulfonic acid
Chemical compound
CS(O)(=O)=O
AFVFQIVMOAPDHO-UHFFFAOYSA-N
0.000
description
2
229930192392
Mitomycin
Natural products
0.000
description
2
PCZOHLXUXFIOCF-UHFFFAOYSA-N
Monacolin X
Natural products
C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1
PCZOHLXUXFIOCF-UHFFFAOYSA-N
0.000
description
2
101000957678
Mus musculus Cytochrome P450 7B1
Proteins
0.000
description
2
208000007101
Muscle Cramp
Diseases
0.000
description
2
NWIBSHFKIJFRCO-WUDYKRTCSA-N
Mytomycin
Chemical compound
C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2
NWIBSHFKIJFRCO-WUDYKRTCSA-N
0.000
description
2
FBWADIKARMIWNM-UHFFFAOYSA-N
N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine
Chemical compound
C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1
FBWADIKARMIWNM-UHFFFAOYSA-N
0.000
description
2
102100022365
NAD(P)H dehydrogenase [quinone] 1
Human genes
0.000
description
2
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
Nicardipine
Chemical compound
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
0.000
description
2
IOVCWXUNBOPUCH-UHFFFAOYSA-M
Nitrite anion
Chemical compound
[O-]N=O
IOVCWXUNBOPUCH-UHFFFAOYSA-M
0.000
description
2
208000001132
Osteoporosis
Diseases
0.000
description
2
208000012868
Overgrowth
Diseases
0.000
description
2
229930012538
Paclitaxel
Natural products
0.000
description
2
229930182555
Penicillin
Natural products
0.000
description
2
JGSARLDLIJGVTE-MBNYWOFBSA-N
Penicillin G
Chemical compound
N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1
JGSARLDLIJGVTE-MBNYWOFBSA-N
0.000
description
2
QZVCTJOXCFMACW-UHFFFAOYSA-N
Phenoxybenzamine
Chemical compound
C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1
QZVCTJOXCFMACW-UHFFFAOYSA-N
0.000
description
2
NBIIXXVUZAFLBC-UHFFFAOYSA-N
Phosphoric acid
Chemical compound
OP(O)(O)=O
NBIIXXVUZAFLBC-UHFFFAOYSA-N
0.000
description
2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
Potassium
Chemical compound
[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
description
2
TUZYXOIXSAXUGO-UHFFFAOYSA-N
Pravastatin
Natural products
C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21
TUZYXOIXSAXUGO-UHFFFAOYSA-N
0.000
description
2
LCTONWCANYUPML-UHFFFAOYSA-N
Pyruvic acid
Chemical compound
CC(=O)C(O)=O
LCTONWCANYUPML-UHFFFAOYSA-N
0.000
description
2
102100038187
RNA binding protein fox-1 homolog 2
Human genes
0.000
description
2
239000012980
RPMI-1640 medium
Substances
0.000
description
2
238000001237
Raman spectrum
Methods
0.000
description
2
101000957679
Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase
Proteins
0.000
description
2
108010052090
Renilla Luciferases
Proteins
0.000
description
2
108091027981
Response element
Proteins
0.000
description
2
208000017442
Retinal disease
Diseases
0.000
description
2
206010038923
Retinopathy
Diseases
0.000
description
2
208000025747
Rheumatic disease
Diseases
0.000
description
2
RYMZZMVNJRMUDD-UHFFFAOYSA-N
SJ000286063
Natural products
C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1
RYMZZMVNJRMUDD-UHFFFAOYSA-N
0.000
description
2
AJLFOPYRIVGYMJ-UHFFFAOYSA-N
SJ000287055
Natural products
C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1
AJLFOPYRIVGYMJ-UHFFFAOYSA-N
0.000
description
2
CDBYLPFSWZWCQE-UHFFFAOYSA-L
Sodium Carbonate
Chemical compound
[Na+].[Na+].[O-]C([O-])=O
CDBYLPFSWZWCQE-UHFFFAOYSA-L
0.000
description
2
102100021993
Sterol O-acyltransferase 1
Human genes
0.000
description
2
101000697584
Streptomyces lavendulae Streptothricin acetyltransferase
Proteins
0.000
description
2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N
Streptozotocin
Natural products
O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O
ZSJLQEPLLKMAKR-UHFFFAOYSA-N
0.000
description
2
QAOWNCQODCNURD-UHFFFAOYSA-N
Sulfuric acid
Chemical compound
OS(O)(=O)=O
QAOWNCQODCNURD-UHFFFAOYSA-N
0.000
description
2
208000018359
Systemic autoimmune disease
Diseases
0.000
description
2
108700012920
TNF
Proteins
0.000
description
2
101100451295
Takifugu rubripes hmox gene
Proteins
0.000
description
2
NAVMQTYZDKMPEU-UHFFFAOYSA-N
Targretin
Chemical compound
CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1
NAVMQTYZDKMPEU-UHFFFAOYSA-N
0.000
description
2
206010043255
Tendonitis
Diseases
0.000
description
2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
Testostosterone
Chemical compound
O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
0.000
description
2
229940123464
Thiazolidinedione
Drugs
0.000
description
2
108010093836
Thioredoxin Reductase 1
Proteins
0.000
description
2
102100031208
Thioredoxin reductase 1, cytoplasmic
Human genes
0.000
description
2
229940123468
Transferase inhibitor
Drugs
0.000
description
2
RTKIYFITIVXBLE-UHFFFAOYSA-N
Trichostatin A
Natural products
ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1
RTKIYFITIVXBLE-UHFFFAOYSA-N
0.000
description
2
XSQUKJJJFZCRTK-UHFFFAOYSA-N
Urea
Chemical compound
NC(N)=O
XSQUKJJJFZCRTK-UHFFFAOYSA-N
0.000
description
2
208000007097
Urinary Bladder Neoplasms
Diseases
0.000
description
2
206010047139
Vasoconstriction
Diseases
0.000
description
2
230000002159
abnormal effect
Effects
0.000
description
2
229960001138
acetylsalicylic acid
Drugs
0.000
description
2
150000007513
acids
Chemical class
0.000
description
2
RJURFGZVJUQBHK-IIXSONLDSA-N
actinomycin D
Chemical compound
C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21
RJURFGZVJUQBHK-IIXSONLDSA-N
0.000
description
2
230000003213
activating effect
Effects
0.000
description
2
208000038016
acute inflammation
Diseases
0.000
description
2
230000006022
acute inflammation
Effects
0.000
description
2
230000032683
aging
Effects
0.000
description
2
239000000556
agonist
Substances
0.000
description
2
229940100198
alkylating agent
Drugs
0.000
description
2
239000002168
alkylating agent
Substances
0.000
description
2
230000004075
alteration
Effects
0.000
description
2
229960000473
altretamine
Drugs
0.000
description
2
WNROFYMDJYEPJX-UHFFFAOYSA-K
aluminium hydroxide
Chemical compound
[OH-].[OH-].[OH-].[Al+3]
WNROFYMDJYEPJX-UHFFFAOYSA-K
0.000
description
2
HTIQEAQVCYTUBX-UHFFFAOYSA-N
amlodipine
Chemical compound
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl
HTIQEAQVCYTUBX-UHFFFAOYSA-N
0.000
description
2
229960000528
amlodipine
Drugs
0.000
description
2
238000005280
amorphization
Methods
0.000
description
2
150000001450
anions
Chemical class
0.000
description
2
CIDNKDMVSINJCG-GKXONYSUSA-N
annamycin
Chemical compound
I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1
CIDNKDMVSINJCG-GKXONYSUSA-N
0.000
description
2
239000003242
anti bacterial agent
Substances
0.000
description
2
230000001315
anti-hyperlipaemic effect
Effects
0.000
description
2
230000003276
anti-hypertensive effect
Effects
0.000
description
2
229940124599
anti-inflammatory drug
Drugs
0.000
description
2
230000000118
anti-neoplastic effect
Effects
0.000
description
2
230000000840
anti-viral effect
Effects
0.000
description
2
239000003529
anticholesteremic agent
Substances
0.000
description
2
229940034982
antineoplastic agent
Drugs
0.000
description
2
210000001742
aqueous humor
Anatomy
0.000
description
2
210000001367
artery
Anatomy
0.000
description
2
239000012131
assay buffer
Substances
0.000
description
2
229960002274
atenolol
Drugs
0.000
description
2
229960005370
atorvastatin
Drugs
0.000
description
2
208000029560
autism spectrum disease
Diseases
0.000
description
2
230000001363
autoimmune
Effects
0.000
description
2
RITAVMQDGBJQJZ-FMIVXFBMSA-N
axitinib
Chemical compound
CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1
RITAVMQDGBJQJZ-FMIVXFBMSA-N
0.000
description
2
229960003005
axitinib
Drugs
0.000
description
2
210000003050
axon
Anatomy
0.000
description
2
230000001580
bacterial effect
Effects
0.000
description
2
229960003094
belinostat
Drugs
0.000
description
2
NCNRHFGMJRPRSK-MDZDMXLPSA-N
belinostat
Chemical compound
ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1
NCNRHFGMJRPRSK-MDZDMXLPSA-N
0.000
description
2
SRSXLGNVWSONIS-UHFFFAOYSA-N
benzenesulfonic acid
Chemical compound
OS(=O)(=O)C1=CC=CC=C1
SRSXLGNVWSONIS-UHFFFAOYSA-N
0.000
description
2
235000010233
benzoic acid
Nutrition
0.000
description
2
229960002938
bexarotene
Drugs
0.000
description
2
230000004071
biological effect
Effects
0.000
description
2
230000031018
biological processes and functions
Effects
0.000
description
2
230000036772
blood pressure
Effects
0.000
description
2
210000004204
blood vessel
Anatomy
0.000
description
2
229960003736
bosutinib
Drugs
0.000
description
2
UBPYILGKFZZVDX-UHFFFAOYSA-N
bosutinib
Chemical compound
C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl
UBPYILGKFZZVDX-UHFFFAOYSA-N
0.000
description
2
229960000455
brentuximab vedotin
Drugs
0.000
description
2
229950005341
bucindolol
Drugs
0.000
description
2
229960002092
busulfan
Drugs
0.000
description
2
239000000480
calcium channel blocker
Substances
0.000
description
2
108010051489
calin
Proteins
0.000
description
2
150000001721
carbon
Chemical class
0.000
description
2
231100000504
carcinogenesis
Toxicity
0.000
description
2
229960005243
carmustine
Drugs
0.000
description
2
NPAKNKYSJIDKMW-UHFFFAOYSA-N
carvedilol
Chemical compound
COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12
NPAKNKYSJIDKMW-UHFFFAOYSA-N
0.000
description
2
229960004195
carvedilol
Drugs
0.000
description
2
150000001768
cations
Chemical class
0.000
description
2
229960002412
cediranib
Drugs
0.000
description
2
239000013592
cell lysate
Substances
0.000
description
2
229940083181
centrally acting adntiadrenergic agent methyldopa
Drugs
0.000
description
2
238000005119
centrifugation
Methods
0.000
description
2
229960005110
cerivastatin
Drugs
0.000
description
2
SEERZIQQUAZTOL-ANMDKAQQSA-N
cerivastatin
Chemical compound
COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1
SEERZIQQUAZTOL-ANMDKAQQSA-N
0.000
description
2
229960004630
chlorambucil
Drugs
0.000
description
2
JCKYGMPEJWAADB-UHFFFAOYSA-N
chlorambucil
Chemical compound
OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1
JCKYGMPEJWAADB-UHFFFAOYSA-N
0.000
description
2
235000012000
cholesterol
Nutrition
0.000
description
2
208000022831
chronic renal failure syndrome
Diseases
0.000
description
2
229960002896
clonidine
Drugs
0.000
description
2
238000004440
column chromatography
Methods
0.000
description
2
239000002872
contrast media
Substances
0.000
description
2
239000003246
corticosteroid
Substances
0.000
description
2
229960001334
corticosteroids
Drugs
0.000
description
2
229940111134
coxibs
Drugs
0.000
description
2
DDRJAANPRJIHGJ-UHFFFAOYSA-N
creatinine
Chemical compound
CN1CC(=O)NC1=N
DDRJAANPRJIHGJ-UHFFFAOYSA-N
0.000
description
2
238000013211
curve analysis
Methods
0.000
description
2
125000004093
cyano group
Chemical group
*C#N
0.000
description
2
239000003255
cyclooxygenase 2 inhibitor
Substances
0.000
description
2
229960000684
cytarabine
Drugs
0.000
description
2
230000001120
cytoprotective effect
Effects
0.000
description
2
229940127096
cytoskeletal disruptor
Drugs
0.000
description
2
230000003013
cytotoxicity
Effects
0.000
description
2
231100000135
cytotoxicity
Toxicity
0.000
description
2
229960003901
dacarbazine
Drugs
0.000
description
2
229960000640
dactinomycin
Drugs
0.000
description
2
229960002448
dasatinib
Drugs
0.000
description
2
229960000975
daunorubicin
Drugs
0.000
description
2
STQGQHZAVUOBTE-VGBVRHCVSA-N
daunorubicin
Chemical compound
O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
STQGQHZAVUOBTE-VGBVRHCVSA-N
0.000
description
2
229960003603
decitabine
Drugs
0.000
description
2
230000007547
defect
Effects
0.000
description
2
230000003412
degenerative effect
Effects
0.000
description
2
238000013461
design
Methods
0.000
description
2
229960003957
dexamethasone
Drugs
0.000
description
2
NIJJYAXOARWZEE-UHFFFAOYSA-N
di-n-propyl-acetic acid
Natural products
CCCC(C(O)=O)CCC
NIJJYAXOARWZEE-UHFFFAOYSA-N
0.000
description
2
238000000502
dialysis
Methods
0.000
description
2
239000003085
diluting agent
Substances
0.000
description
2
XEYBRNLFEZDVAW-ARSRFYASSA-N
dinoprostone
Chemical compound
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
XEYBRNLFEZDVAW-ARSRFYASSA-N
0.000
description
2
208000037765
diseases and disorders
Diseases
0.000
description
2
239000006185
dispersion
Substances
0.000
description
2
239000003534
dna topoisomerase inhibitor
Substances
0.000
description
2
OFDNQWIFNXBECV-VFSYNPLYSA-N
dolastatin 10
Chemical compound
CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1
OFDNQWIFNXBECV-VFSYNPLYSA-N
0.000
description
2
108010045524
dolastatin 10
Proteins
0.000
description
2
RUZYUOTYCVRMRZ-UHFFFAOYSA-N
doxazosin
Chemical compound
C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N
0.000
description
2
229960001389
doxazosin
Drugs
0.000
description
2
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
doxifluridine
Chemical compound
O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
0.000
description
2
229950005454
doxifluridine
Drugs
0.000
description
2
229940000406
drug candidate
Drugs
0.000
description
2
208000020947
enthesitis
Diseases
0.000
description
2
INVTYAOGFAGBOE-UHFFFAOYSA-N
entinostat
Chemical compound
NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1
INVTYAOGFAGBOE-UHFFFAOYSA-N
0.000
description
2
210000002919
epithelial cell
Anatomy
0.000
description
2
229960001433
erlotinib
Drugs
0.000
description
2
AAKJLRGGTJKAMG-UHFFFAOYSA-N
erlotinib
Chemical compound
C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1
AAKJLRGGTJKAMG-UHFFFAOYSA-N
0.000
description
2
239000002834
estrogen receptor modulator
Substances
0.000
description
2
OLNTVTPDXPETLC-XPWALMASSA-N
ezetimibe
Chemical compound
N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1
OLNTVTPDXPETLC-XPWALMASSA-N
0.000
description
2
229960000815
ezetimibe
Drugs
0.000
description
2
229960003580
felodipine
Drugs
0.000
description
2
230000003176
fibrotic effect
Effects
0.000
description
2
229960003765
fluvastatin
Drugs
0.000
description
2
229960002584
gefitinib
Drugs
0.000
description
2
XGALLCVXEZPNRQ-UHFFFAOYSA-N
gefitinib
Chemical compound
C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1
XGALLCVXEZPNRQ-UHFFFAOYSA-N
0.000
description
2
229960003297
gemtuzumab ozogamicin
Drugs
0.000
description
2
238000001415
gene therapy
Methods
0.000
description
2
238000007429
general method
Methods
0.000
description
2
BRZYSWJRSDMWLG-CAXSIQPQSA-N
geneticin
Chemical compound
O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N
BRZYSWJRSDMWLG-CAXSIQPQSA-N
0.000
description
2
230000004153
glucose metabolism
Effects
0.000
description
2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N
hexamethylmelamine
Chemical compound
CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N
0.000
description
2
229940121372
histone deacetylase inhibitor
Drugs
0.000
description
2
239000003276
histone deacetylase inhibitor
Substances
0.000
description
2
229930182851
human metabolite
Natural products
0.000
description
2
125000004435
hydrogen atom
Chemical group
[H]*
0.000
description
2
230000007062
hydrolysis
Effects
0.000
description
2
238000006460
hydrolysis reaction
Methods
0.000
description
2
150000002440
hydroxy compounds
Chemical class
0.000
description
2
230000033444
hydroxylation
Effects
0.000
description
2
238000005805
hydroxylation reaction
Methods
0.000
description
2
230000002218
hypoglycaemic effect
Effects
0.000
description
2
229960001001
ibritumomab tiuxetan
Drugs
0.000
description
2
229960000908
idarubicin
Drugs
0.000
description
2
KTUFNOKKBVMGRW-UHFFFAOYSA-N
imatinib
Chemical compound
C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1
KTUFNOKKBVMGRW-UHFFFAOYSA-N
0.000
description
2
229960002411
imatinib
Drugs
0.000
description
2
125000001841
imino group
Chemical group
[H]N=*
0.000
description
2
230000002519
immonomodulatory effect
Effects
0.000
description
2
210000002865
immune cell
Anatomy
0.000
description
2
230000028993
immune response
Effects
0.000
description
2
210000000987
immune system
Anatomy
0.000
description
2
229960002056
indoramin
Drugs
0.000
description
2
239000000411
inducer
Substances
0.000
description
2
230000002458
infectious effect
Effects
0.000
description
2
230000008595
infiltration
Effects
0.000
description
2
238000001764
infiltration
Methods
0.000
description
2
206010022000
influenza
Diseases
0.000
description
2
150000007529
inorganic bases
Chemical class
0.000
description
2
239000000543
intermediate
Substances
0.000
description
2
230000000968
intestinal effect
Effects
0.000
description
2
238000007912
intraperitoneal administration
Methods
0.000
description
2
239000007928
intraperitoneal injection
Substances
0.000
description
2
229960005280
isotretinoin
Drugs
0.000
description
2
FABUFPQFXZVHFB-CFWQTKTJSA-N
ixabepilone
Chemical compound
C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1
FABUFPQFXZVHFB-CFWQTKTJSA-N
0.000
description
2
229960002014
ixabepilone
Drugs
0.000
description
2
229960001632
labetalol
Drugs
0.000
description
2
GKQPCPXONLDCMU-CCEZHUSRSA-N
lacidipine
Chemical compound
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C
GKQPCPXONLDCMU-CCEZHUSRSA-N
0.000
description
2
229960004340
lacidipine
Drugs
0.000
description
2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N
lactic acid
Chemical compound
CC(O)C(O)=O
JVTAAEKCZFNVCJ-UHFFFAOYSA-N
0.000
description
2
229960004891
lapatinib
Drugs
0.000
description
2
ZDXUKAKRHYTAKV-UHFFFAOYSA-N
lercanidipine
Chemical compound
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1
ZDXUKAKRHYTAKV-UHFFFAOYSA-N
0.000
description
2
229960004294
lercanidipine
Drugs
0.000
description
2
230000003902
lesion
Effects
0.000
description
2
238000004895
liquid chromatography mass spectrometry
Methods
0.000
description
2
208000007903
liver failure
Diseases
0.000
description
2
231100000835
liver failure
Toxicity
0.000
description
2
229960002247
lomustine
Drugs
0.000
description
2
PCZOHLXUXFIOCF-BXMDZJJMSA-N
lovastatin
Chemical compound
C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1
PCZOHLXUXFIOCF-BXMDZJJMSA-N
0.000
description
2
229960004844
lovastatin
Drugs
0.000
description
2
QLJODMDSTUBWDW-UHFFFAOYSA-N
lovastatin hydroxy acid
Natural products
C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21
QLJODMDSTUBWDW-UHFFFAOYSA-N
0.000
description
2
238000004020
luminiscence type
Methods
0.000
description
2
208000024714
major depressive disease
Diseases
0.000
description
2
239000003550
marker
Substances
0.000
description
2
108010082117
matrigel
Proteins
0.000
description
2
230000035800
maturation
Effects
0.000
description
2
230000007246
mechanism
Effects
0.000
description
2
HAWPXGHAZFHHAD-UHFFFAOYSA-N
mechlorethamine
Chemical compound
ClCCN(C)CCCl
HAWPXGHAZFHHAD-UHFFFAOYSA-N
0.000
description
2
229960004961
mechlorethamine
Drugs
0.000
description
2
238000002844
melting
Methods
0.000
description
2
230000008018
melting
Effects
0.000
description
2
GLVAUDGFNGKCSF-UHFFFAOYSA-N
mercaptopurine
Chemical compound
S=C1NC=NC2=C1NC=N2
GLVAUDGFNGKCSF-UHFFFAOYSA-N
0.000
description
2
229960001428
mercaptopurine
Drugs
0.000
description
2
KBOPZPXVLCULAV-UHFFFAOYSA-N
mesalamine
Chemical class
NC1=CC=C(O)C(C(O)=O)=C1
KBOPZPXVLCULAV-UHFFFAOYSA-N
0.000
description
2
230000009401
metastasis
Effects
0.000
description
2
VKQFCGNPDRICFG-UHFFFAOYSA-N
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Chemical compound
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O
VKQFCGNPDRICFG-UHFFFAOYSA-N
0.000
description
2
IUBSYMUCCVWXPE-UHFFFAOYSA-N
metoprolol
Chemical compound
COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
IUBSYMUCCVWXPE-UHFFFAOYSA-N
0.000
description
2
229960002237
metoprolol
Drugs
0.000
description
2
AJLFOPYRIVGYMJ-INTXDZFKSA-N
mevastatin
Chemical compound
C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1
AJLFOPYRIVGYMJ-INTXDZFKSA-N
0.000
description
2
229950009116
mevastatin
Drugs
0.000
description
2
BOZILQFLQYBIIY-UHFFFAOYSA-N
mevastatin hydroxy acid
Natural products
C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21
BOZILQFLQYBIIY-UHFFFAOYSA-N
0.000
description
2
244000005700
microbiome
Species
0.000
description
2
230000002025
microglial effect
Effects
0.000
description
2
235000013336
milk
Nutrition
0.000
description
2
239000008267
milk
Substances
0.000
description
2
210000004080
milk
Anatomy
0.000
description
2
244000309715
mini pig
Species
0.000
description
2
CFCUWKMKBJTWLW-BKHRDMLASA-N
mithramycin
Chemical compound
O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1
CFCUWKMKBJTWLW-BKHRDMLASA-N
0.000
description
2
229960004857
mitomycin
Drugs
0.000
description
2
230000004048
modification
Effects
0.000
description
2
238000012986
modification
Methods
0.000
description
2
210000000214
mouth
Anatomy
0.000
description
2
TXXHDPDFNKHHGW-UHFFFAOYSA-N
muconic acid
Chemical compound
OC(=O)C=CC=CC(O)=O
TXXHDPDFNKHHGW-UHFFFAOYSA-N
0.000
description
2
210000004877
mucosa
Anatomy
0.000
description
2
201000006938
muscular dystrophy
Diseases
0.000
description
2
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
nadolol
Chemical compound
C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
0.000
description
2
229960004255
nadolol
Drugs
0.000
description
2
229950008835
neratinib
Drugs
0.000
description
2
JWNPDZNEKVCWMY-VQHVLOKHSA-N
neratinib
Chemical compound
C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1
JWNPDZNEKVCWMY-VQHVLOKHSA-N
0.000
description
2
230000001537
neural effect
Effects
0.000
description
2
208000004296
neuralgia
Diseases
0.000
description
2
230000000626
neurodegenerative effect
Effects
0.000
description
2
208000021722
neuropathic pain
Diseases
0.000
description
2
201000001119
neuropathy
Diseases
0.000
description
2
230000007823
neuropathy
Effects
0.000
description
2
210000000440
neutrophil
Anatomy
0.000
description
2
229960001783
nicardipine
Drugs
0.000
description
2
HYIMSNHJOBLJNT-UHFFFAOYSA-N
nifedipine
Chemical compound
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O
HYIMSNHJOBLJNT-UHFFFAOYSA-N
0.000
description
2
229960001597
nifedipine
Drugs
0.000
description
2
HHZIURLSWUIHRB-UHFFFAOYSA-N
nilotinib
Chemical compound
C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1
HHZIURLSWUIHRB-UHFFFAOYSA-N
0.000
description
2
229960001346
nilotinib
Drugs
0.000
description
2
229960000715
nimodipine
Drugs
0.000
description
2
229960000227
nisoldipine
Drugs
0.000
description
2
229960005425
nitrendipine
Drugs
0.000
description
2
OSTGTTZJOCZWJG-UHFFFAOYSA-N
nitrosourea
Chemical compound
NC(=O)N=NO
OSTGTTZJOCZWJG-UHFFFAOYSA-N
0.000
description
2
150000007530
organic bases
Chemical class
0.000
description
2
150000002894
organic compounds
Chemical class
0.000
description
2
230000002018
overexpression
Effects
0.000
description
2
230000001590
oxidative effect
Effects
0.000
description
2
229960004570
oxprenolol
Drugs
0.000
description
2
229960001592
paclitaxel
Drugs
0.000
description
2
229960001972
panitumumab
Drugs
0.000
description
2
229960005184
panobinostat
Drugs
0.000
description
2
FWZRWHZDXBDTFK-ZHACJKMWSA-N
panobinostat
Chemical compound
CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1
FWZRWHZDXBDTFK-ZHACJKMWSA-N
0.000
description
2
229940049954
penicillin
Drugs
0.000
description
2
208000033808
peripheral neuropathy
Diseases
0.000
description
2
102000013415
peroxidase activity proteins
Human genes
0.000
description
2
108040007629
peroxidase activity proteins
Proteins
0.000
description
2
230000002688
persistence
Effects
0.000
description
2
239000012071
phase
Substances
0.000
description
2
CPJSUEIXXCENMM-UHFFFAOYSA-N
phenacetin
Chemical compound
CCOC1=CC=C(NC(C)=O)C=C1
CPJSUEIXXCENMM-UHFFFAOYSA-N
0.000
description
2
229960003418
phenoxybenzamine
Drugs
0.000
description
2
MRBDMNSDAVCSSF-UHFFFAOYSA-N
phentolamine
Chemical compound
C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1
MRBDMNSDAVCSSF-UHFFFAOYSA-N
0.000
description
2
229960001999
phentolamine
Drugs
0.000
description
2
NBIIXXVUZAFLBC-UHFFFAOYSA-K
phosphate
Chemical compound
[O-]P([O-])([O-])=O
NBIIXXVUZAFLBC-UHFFFAOYSA-K
0.000
description
2
239000010452
phosphate
Substances
0.000
description
2
PHUTUTUABXHXLW-UHFFFAOYSA-N
pindolol
Chemical compound
CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12
PHUTUTUABXHXLW-UHFFFAOYSA-N
0.000
description
2
229960002508
pindolol
Drugs
0.000
description
2
229960002797
pitavastatin
Drugs
0.000
description
2
VGYFMXBACGZSIL-MCBHFWOFSA-N
pitavastatin
Chemical compound
OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1
VGYFMXBACGZSIL-MCBHFWOFSA-N
0.000
description
2
229960003171
plicamycin
Drugs
0.000
description
2
229920001223
polyethylene glycol
Polymers
0.000
description
2
235000010482
polyoxyethylene sorbitan monooleate
Nutrition
0.000
description
2
229920000053
polysorbate 80
Polymers
0.000
description
2
239000011591
potassium
Substances
0.000
description
2
229910052700
potassium
Inorganic materials
0.000
description
2
229960002965
pravastatin
Drugs
0.000
description
2
TUZYXOIXSAXUGO-PZAWKZKUSA-N
pravastatin
Chemical compound
C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21
TUZYXOIXSAXUGO-PZAWKZKUSA-N
0.000
description
2
IENZQIKPVFGBNW-UHFFFAOYSA-N
prazosin
Chemical compound
N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1
IENZQIKPVFGBNW-UHFFFAOYSA-N
0.000
description
2
229960001289
prazosin
Drugs
0.000
description
2
230000003244
pro-oxidative effect
Effects
0.000
description
2
CPTBDICYNRMXFX-UHFFFAOYSA-N
procarbazine
Chemical compound
CNNCC1=CC=C(C(=O)NC(C)C)C=C1
CPTBDICYNRMXFX-UHFFFAOYSA-N
0.000
description
2
229960000624
procarbazine
Drugs
0.000
description
2
230000001737
promoting effect
Effects
0.000
description
2
229960003712
propranolol
Drugs
0.000
description
2
230000009325
pulmonary function
Effects
0.000
description
2
238000000746
purification
Methods
0.000
description
2
238000011552
rat model
Methods
0.000
description
2
229940075993
receptor modulator
Drugs
0.000
description
2
102000005962
receptors
Human genes
0.000
description
2
108020003175
receptors
Proteins
0.000
description
2
230000007115
recruitment
Effects
0.000
description
2
230000010410
reperfusion
Effects
0.000
description
2
230000010076
replication
Effects
0.000
description
2
229930002330
retinoic acid
Natural products
0.000
description
2
102000027483
retinoid hormone receptors
Human genes
0.000
description
2
108091008679
retinoid hormone receptors
Proteins
0.000
description
2
229960000672
rosuvastatin
Drugs
0.000
description
2
BPRHUIZQVSMCRT-VEUZHWNKSA-N
rosuvastatin
Chemical compound
CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O
BPRHUIZQVSMCRT-VEUZHWNKSA-N
0.000
description
2
YGSDEFSMJLZEOE-UHFFFAOYSA-N
salicylic acid
Chemical compound
OC(=O)C1=CC=CC=C1O
YGSDEFSMJLZEOE-UHFFFAOYSA-N
0.000
description
2
201000000980
schizophrenia
Diseases
0.000
description
2
239000000849
selective androgen receptor modulator
Substances
0.000
description
2
229950003647
semaxanib
Drugs
0.000
description
2
WUWDLXZGHZSWQZ-WQLSENKSSA-N
semaxanib
Chemical compound
N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O
WUWDLXZGHZSWQZ-WQLSENKSSA-N
0.000
description
2
229960003440
semustine
Drugs
0.000
description
2
RYMZZMVNJRMUDD-HGQWONQESA-N
simvastatin
Chemical compound
C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1
RYMZZMVNJRMUDD-HGQWONQESA-N
0.000
description
2
229960002855
simvastatin
Drugs
0.000
description
2
MFBOGIVSZKQAPD-UHFFFAOYSA-M
sodium butyrate
Chemical compound
[Na+].CCCC([O-])=O
MFBOGIVSZKQAPD-UHFFFAOYSA-M
0.000
description
2
229940006198
sodium phenylacetate
Drugs
0.000
description
2
239000011343
solid material
Substances
0.000
description
2
238000000638
solvent extraction
Methods
0.000
description
2
238000004611
spectroscopical analysis
Methods
0.000
description
2
230000004936
stimulating effect
Effects
0.000
description
2
238000003860
storage
Methods
0.000
description
2
229960001052
streptozocin
Drugs
0.000
description
2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
streptozocin
Chemical compound
O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
0.000
description
2
238000007920
subcutaneous administration
Methods
0.000
description
2
229910052717
sulfur
Inorganic materials
0.000
description
2
WINHZLLDWRZWRT-ATVHPVEESA-N
sunitinib
Chemical compound
CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C
WINHZLLDWRZWRT-ATVHPVEESA-N
0.000
description
2
229960001796
sunitinib
Drugs
0.000
description
2
210000001179
synovial fluid
Anatomy
0.000
description
2
201000004595
synovitis
Diseases
0.000
description
2
229960001603
tamoxifen
Drugs
0.000
description
2
RCINICONZNJXQF-MZXODVADSA-N
taxol
Chemical compound
O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1
RCINICONZNJXQF-MZXODVADSA-N
0.000
description
2
NRUKOCRGYNPUPR-QBPJDGROSA-N
teniposide
Chemical compound
COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1
NRUKOCRGYNPUPR-QBPJDGROSA-N
0.000
description
2
229960001278
teniposide
Drugs
0.000
description
2
VCKUSRYTPJJLNI-UHFFFAOYSA-N
terazosin
Chemical compound
N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1
VCKUSRYTPJJLNI-UHFFFAOYSA-N
0.000
description
2
229960001693
terazosin
Drugs
0.000
description
2
150000001467
thiazolidinediones
Chemical class
0.000
description
2
229960004605
timolol
Drugs
0.000
description
2
MNRILEROXIRVNJ-UHFFFAOYSA-N
tioguanine
Chemical compound
N1C(N)=NC(=S)C2=NC=N[C]21
MNRILEROXIRVNJ-UHFFFAOYSA-N
0.000
description
2
229960003087
tioguanine
Drugs
0.000
description
2
208000037816
tissue injury
Diseases
0.000
description
2
JIVZKJJQOZQXQB-UHFFFAOYSA-N
tolazoline
Chemical compound
C=1C=CC=CC=1CC1=NCCN1
JIVZKJJQOZQXQB-UHFFFAOYSA-N
0.000
description
2
229960002312
tolazoline
Drugs
0.000
description
2
229940044693
topoisomerase inhibitor
Drugs
0.000
description
2
229960005267
tositumomab
Drugs
0.000
description
2
VZCYOOQTPOCHFL-UHFFFAOYSA-N
trans-butenedioic acid
Natural products
OC(=O)C=CC(O)=O
VZCYOOQTPOCHFL-UHFFFAOYSA-N
0.000
description
2
238000001890
transfection
Methods
0.000
description
2
239000003558
transferase inhibitor
Substances
0.000
description
2
229960001612
trastuzumab emtansine
Drugs
0.000
description
2
229960001727
tretinoin
Drugs
0.000
description
2
RTKIYFITIVXBLE-QEQCGCAPSA-N
trichostatin A
Chemical compound
ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1
RTKIYFITIVXBLE-QEQCGCAPSA-N
0.000
description
2
229940121358
tyrosine kinase inhibitor
Drugs
0.000
description
2
239000005483
tyrosine kinase inhibitor
Substances
0.000
description
2
150000004917
tyrosine kinase inhibitor derivatives
Chemical class
0.000
description
2
230000036269
ulceration
Effects
0.000
description
2
MSRILKIQRXUYCT-UHFFFAOYSA-M
valproate semisodium
Chemical compound
[Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC
MSRILKIQRXUYCT-UHFFFAOYSA-M
0.000
description
2
229960000604
valproic acid
Drugs
0.000
description
2
229960000653
valrubicin
Drugs
0.000
description
2
ZOCKGBMQLCSHFP-KQRAQHLDSA-N
valrubicin
Chemical compound
O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1
ZOCKGBMQLCSHFP-KQRAQHLDSA-N
0.000
description
2
UHTHHESEBZOYNR-UHFFFAOYSA-N
vandetanib
Chemical compound
COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1
UHTHHESEBZOYNR-UHFFFAOYSA-N
0.000
description
2
229960000241
vandetanib
Drugs
0.000
description
2
230000025033
vasoconstriction
Effects
0.000
description
2
OGWKCGZFUXNPDA-XQKSVPLYSA-N
vincristine
Chemical compound
C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12
OGWKCGZFUXNPDA-XQKSVPLYSA-N
0.000
description
2
229960004528
vincristine
Drugs
0.000
description
2
OGWKCGZFUXNPDA-UHFFFAOYSA-N
vincristine
Natural products
C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12
OGWKCGZFUXNPDA-UHFFFAOYSA-N
0.000
description
2
UGGWPQSBPIFKDZ-KOTLKJBCSA-N
vindesine
Chemical compound
C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N
0.000
description
2
229960004355
vindesine
Drugs
0.000
description
2
230000029812
viral genome replication
Effects
0.000
description
2
WAEXFXRVDQXREF-UHFFFAOYSA-N
vorinostat
Chemical compound
ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
WAEXFXRVDQXREF-UHFFFAOYSA-N
0.000
description
2
229960000237
vorinostat
Drugs
0.000
description
2
235000012431
wafers
Nutrition
0.000
description
2
239000003643
water by type
Substances
0.000
description
2
235000019786
weight gain
Nutrition
0.000
description
2
208000016261
weight loss
Diseases
0.000
description
2
230000004580
weight loss
Effects
0.000
description
2
238000001262
western blot
Methods
0.000
description
2
230000029663
wound healing
Effects
0.000
description
2
QBYIENPQHBMVBV-HFEGYEGKSA-N
(2R)-2-hydroxy-2-phenylacetic acid
Chemical compound
O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1
QBYIENPQHBMVBV-HFEGYEGKSA-N
0.000
description
1
AAWZDTNXLSGCEK-LNVDRNJUSA-N
(3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid
Chemical class
O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O
AAWZDTNXLSGCEK-LNVDRNJUSA-N
0.000
description
1
XBZYWSMVVKYHQN-MYPRUECHSA-N
(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid
Chemical compound
C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C
XBZYWSMVVKYHQN-MYPRUECHSA-N
0.000
description
1
MIOPJNTWMNEORI-GMSGAONNSA-N
(S)-camphorsulfonic acid
Chemical compound
C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C
MIOPJNTWMNEORI-GMSGAONNSA-N
0.000
description
1
BJEPYKJPYRNKOW-REOHCLBHSA-N
(S)-malic acid
Chemical compound
OC(=O)[C@@H](O)CC(O)=O
BJEPYKJPYRNKOW-REOHCLBHSA-N
0.000
description
1
AWSUSADYFDCYML-KUPUPYBPSA-N
(z)-7-[(1s,5r)-5-[(e)-oct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
Chemical compound
CCCCCC\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O
AWSUSADYFDCYML-KUPUPYBPSA-N
0.000
description
1
WBYWAXJHAXSJNI-VOTSOKGWSA-M
.beta-Phenylacrylic acid
Natural products
[O-]C(=O)\C=C\C1=CC=CC=C1
WBYWAXJHAXSJNI-VOTSOKGWSA-M
0.000
description
1
AMMPLVWPWSYRDR-UHFFFAOYSA-N
1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid
Chemical compound
C1CC2(C(O)=O)CCC1(C)C=C2
AMMPLVWPWSYRDR-UHFFFAOYSA-N
0.000
description
1
XJGBNZRVGOENRN-UHFFFAOYSA-N
2,2-difluoropropanamide
Chemical class
CC(F)(F)C(N)=O
XJGBNZRVGOENRN-UHFFFAOYSA-N
0.000
description
1
NTOIKDYVJIWVSU-UHFFFAOYSA-N
2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid
Chemical class
C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1
NTOIKDYVJIWVSU-UHFFFAOYSA-N
0.000
description
1
WXTMDXOMEHJXQO-UHFFFAOYSA-N
2,5-dihydroxybenzoic acid
Chemical class
OC(=O)C1=CC(O)=CC=C1O
WXTMDXOMEHJXQO-UHFFFAOYSA-N
0.000
description
1
MNURPFVONZPVLA-UHFFFAOYSA-N
2-chlorobenzenesulfonic acid
Chemical compound
OS(=O)(=O)C1=CC=CC=C1Cl
MNURPFVONZPVLA-UHFFFAOYSA-N
0.000
description
1
UPHOPMSGKZNELG-UHFFFAOYSA-N
2-hydroxynaphthalene-1-carboxylic acid
Chemical compound
C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1
UPHOPMSGKZNELG-UHFFFAOYSA-N
0.000
description
1
WUIABRMSWOKTOF-OYALTWQYSA-N
3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox
Chemical compound
OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C
WUIABRMSWOKTOF-OYALTWQYSA-N
0.000
description
1
BMYNFMYTOJXKLE-UHFFFAOYSA-N
3-azaniumyl-2-hydroxypropanoate
Chemical compound
NCC(O)C(O)=O
BMYNFMYTOJXKLE-UHFFFAOYSA-N
0.000
description
1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N
3-cyclopentylpropionic acid
Chemical compound
OC(=O)CCC1CCCC1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N
0.000
description
1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N
4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid
Chemical compound
C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N
0.000
description
1
AWQSAIIDOMEEOD-UHFFFAOYSA-N
5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone
Chemical compound
CC(=O)CCC1CC(=O)OC1(C)C
AWQSAIIDOMEEOD-UHFFFAOYSA-N
0.000
description
1
IJJWOSAXNHWBPR-HUBLWGQQSA-N
5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide
Chemical compound
N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21
IJJWOSAXNHWBPR-HUBLWGQQSA-N
0.000
description
1
102100033350
ATP-dependent translocase ABCB1
Human genes
0.000
description
1
208000004611
Abdominal Obesity
Diseases
0.000
description
1
208000004476
Acute Coronary Syndrome
Diseases
0.000
description
1
108010062271
Acute-Phase Proteins
Proteins
0.000
description
1
102000011767
Acute-Phase Proteins
Human genes
0.000
description
1
206010001197
Adenocarcinoma of the cervix
Diseases
0.000
description
1
208000034246
Adenocarcinoma of the cervix uteri
Diseases
0.000
description
1
108700028369
Alleles
Proteins
0.000
description
1
102100022524
Alpha-1-antichymotrypsin
Human genes
0.000
description
1
206010002198
Anaphylactic reaction
Diseases
0.000
description
1
208000008822
Ankylosis
Diseases
0.000
description
1
208000000103
Anorexia Nervosa
Diseases
0.000
description
1
YZXBAPSDXZZRGB-DOFZRALJSA-M
Arachidonate
Chemical compound
CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O
YZXBAPSDXZZRGB-DOFZRALJSA-M
0.000
description
1
239000004475
Arginine
Substances
0.000
description
1
208000006820
Arthralgia
Diseases
0.000
description
1
208000036487
Arthropathies
Diseases
0.000
description
1
DGAKHGXRMXWHBX-ONEGZZNKSA-N
Azoxymethane
Chemical compound
C\N=[N+](/C)[O-]
DGAKHGXRMXWHBX-ONEGZZNKSA-N
0.000
description
1
GWZYPXHJIZCRAJ-UHFFFAOYSA-N
Biliverdin
Natural products
CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O
GWZYPXHJIZCRAJ-UHFFFAOYSA-N
0.000
description
1
RCNSAJSGRJSBKK-NSQVQWHSSA-N
Biliverdin IX
Chemical compound
N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1
RCNSAJSGRJSBKK-NSQVQWHSSA-N
0.000
description
1
208000020084
Bone disease
Diseases
0.000
description
1
206010006187
Breast cancer
Diseases
0.000
description
1
208000026310
Breast neoplasm
Diseases
0.000
description
1
102100021943
C-C motif chemokine 2
Human genes
0.000
description
1
101710155857
C-C motif chemokine 2
Proteins
0.000
description
1
102100036846
C-C motif chemokine 21
Human genes
0.000
description
1
102100031658
C-X-C chemokine receptor type 5
Human genes
0.000
description
1
206010006895
Cachexia
Diseases
0.000
description
1
241000754798
Calophyllum brasiliense
Species
0.000
description
1
WWZKQHOCKIZLMA-UHFFFAOYSA-N
Caprylic acid
Natural products
CCCCCCCC(O)=O
WWZKQHOCKIZLMA-UHFFFAOYSA-N
0.000
description
1
CURLTUGMZLYLDI-UHFFFAOYSA-N
Carbon dioxide
Chemical compound
O=C=O
CURLTUGMZLYLDI-UHFFFAOYSA-N
0.000
description
1
208000005623
Carcinogenesis
Diseases
0.000
description
1
206010007558
Cardiac failure chronic
Diseases
0.000
description
1
206010007572
Cardiac hypertrophy
Diseases
0.000
description
1
208000006029
Cardiomegaly
Diseases
0.000
description
1
208000031229
Cardiomyopathies
Diseases
0.000
description
1
108010078791
Carrier Proteins
Proteins
0.000
description
1
206010065941
Central obesity
Diseases
0.000
description
1
LZZYPRNAOMGNLH-UHFFFAOYSA-M
Cetrimonium bromide
Chemical compound
[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C
LZZYPRNAOMGNLH-UHFFFAOYSA-M
0.000
description
1
WBYWAXJHAXSJNI-SREVYHEPSA-N
Cinnamic acid
Chemical compound
OC(=O)\C=C/C1=CC=CC=C1
WBYWAXJHAXSJNI-SREVYHEPSA-N
0.000
description
1
206010048832
Colon adenoma
Diseases
0.000
description
1
102000000989
Complement System Proteins
Human genes
0.000
description
1
108010069112
Complement System Proteins
Proteins
0.000
description
1
208000002330
Congenital Heart Defects
Diseases
0.000
description
1
206010010774
Constipation
Diseases
0.000
description
1
XDTMQSROBMDMFD-UHFFFAOYSA-N
Cyclohexane
Chemical compound
C1CCCCC1
XDTMQSROBMDMFD-UHFFFAOYSA-N
0.000
description
1
PMATZTZNYRCHOR-CGLBZJNRSA-N
Cyclosporin A
Chemical compound
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O
PMATZTZNYRCHOR-CGLBZJNRSA-N
0.000
description
1
108010036949
Cyclosporine
Proteins
0.000
description
1
102000008144
Cytochrome P-450 CYP1A2
Human genes
0.000
description
1
108010026925
Cytochrome P-450 CYP2C19
Proteins
0.000
description
1
108010000561
Cytochrome P-450 CYP2C8
Proteins
0.000
description
1
108010000543
Cytochrome P-450 CYP2C9
Proteins
0.000
description
1
108010001237
Cytochrome P-450 CYP2D6
Proteins
0.000
description
1
102100029363
Cytochrome P450 2C19
Human genes
0.000
description
1
102100029359
Cytochrome P450 2C8
Human genes
0.000
description
1
102100029358
Cytochrome P450 2C9
Human genes
0.000
description
1
102100021704
Cytochrome P450 2D6
Human genes
0.000
description
1
108010026759
Cytoplasmic Aspartate Aminotransferase
Proteins
0.000
description
1
RGHNJXZEOKUKBD-UHFFFAOYSA-N
D-gluconic acid
Natural products
OCC(O)C(O)C(O)C(O)C(O)=O
RGHNJXZEOKUKBD-UHFFFAOYSA-N
0.000
description
1
YZCKVEUIGOORGS-OUBTZVSYSA-N
Deuterium
Chemical compound
[2H]
YZCKVEUIGOORGS-OUBTZVSYSA-N
0.000
description
1
FEWJPZIEWOKRBE-JCYAYHJZSA-N
Dextrotartaric acid
Chemical compound
OC(=O)[C@H](O)[C@@H](O)C(O)=O
FEWJPZIEWOKRBE-JCYAYHJZSA-N
0.000
description
1
208000007342
Diabetic Nephropathies
Diseases
0.000
description
1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N
Diisopropyl ether
Chemical compound
CC(C)OC(C)C
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N
0.000
description
1
208000035762
Disorder of lipid metabolism
Diseases
0.000
description
1
206010013710
Drug interaction
Diseases
0.000
description
1
208000030814
Eating disease
Diseases
0.000
description
1
206010048554
Endothelial dysfunction
Diseases
0.000
description
1
208000004232
Enteritis
Diseases
0.000
description
1
241000283073
Equus caballus
Species
0.000
description
1
244000187656
Eucalyptus cornuta
Species
0.000
description
1
208000010201
Exanthema
Diseases
0.000
description
1
206010015866
Extravasation
Diseases
0.000
description
1
208000019454
Feeding and Eating disease
Diseases
0.000
description
1
101150005894
GCLC gene
Proteins
0.000
description
1
201000000628
Gas Gangrene
Diseases
0.000
description
1
206010061166
Gastroenteritis bacterial
Diseases
0.000
description
1
208000012671
Gastrointestinal haemorrhages
Diseases
0.000
description
1
101150038307
Gclm gene
Proteins
0.000
description
1
108700028146
Genetic Enhancer Elements
Proteins
0.000
description
1
108700039691
Genetic Promoter Regions
Proteins
0.000
description
1
102000016354
Glucuronosyltransferase
Human genes
0.000
description
1
108010092364
Glucuronosyltransferase
Proteins
0.000
description
1
102000004263
Glutamate-Cysteine Ligase
Human genes
0.000
description
1
102100039696
Glutamate-cysteine ligase catalytic subunit
Human genes
0.000
description
1
WHUUTDBJXJRKMK-UHFFFAOYSA-N
Glutamic acid
Natural products
OC(=O)C(N)CCC(O)=O
WHUUTDBJXJRKMK-UHFFFAOYSA-N
0.000
description
1
238000006595
Griess deamination reaction
Methods
0.000
description
1
102000015779
HDL Lipoproteins
Human genes
0.000
description
1
102000012153
HLA-B27 Antigen
Human genes
0.000
description
1
108010061486
HLA-B27 Antigen
Proteins
0.000
description
1
102000016761
Haem oxygenases
Human genes
0.000
description
1
108050006318
Haem oxygenases
Proteins
0.000
description
1
101000779415
Homo sapiens Alanine aminotransferase 2
Proteins
0.000
description
1
101000678026
Homo sapiens Alpha-1-antichymotrypsin
Proteins
0.000
description
1
101000929698
Homo sapiens Aspartate aminotransferase, cytoplasmic
Proteins
0.000
description
1
101000713085
Homo sapiens C-C motif chemokine 21
Proteins
0.000
description
1
101000922405
Homo sapiens C-X-C chemokine receptor type 5
Proteins
0.000
description
1
101001034527
Homo sapiens Glutamate-cysteine ligase catalytic subunit
Proteins
0.000
description
1
101001055222
Homo sapiens Interleukin-8
Proteins
0.000
description
1
101100026727
Homo sapiens NQO1 gene
Proteins
0.000
description
1
101150020741
Hpgds gene
Proteins
0.000
description
1
206010058490
Hyperoxia
Diseases
0.000
description
1
201000002980
Hyperparathyroidism
Diseases
0.000
description
1
206010020751
Hypersensitivity
Diseases
0.000
description
1
206010020880
Hypertrophy
Diseases
0.000
description
1
206010021143
Hypoxia
Diseases
0.000
description
1
HEFNNWSXXWATRW-UHFFFAOYSA-N
Ibuprofen
Chemical compound
CC(C)CC1=CC=C(C(C)C(O)=O)C=C1
HEFNNWSXXWATRW-UHFFFAOYSA-N
0.000
description
1
206010062016
Immunosuppression
Diseases
0.000
description
1
206010065390
Inflammatory pain
Diseases
0.000
description
1
108010065805
Interleukin-12
Proteins
0.000
description
1
102000013462
Interleukin-12
Human genes
0.000
description
1
108090001007
Interleukin-8
Proteins
0.000
description
1
102000004890
Interleukin-8
Human genes
0.000
description
1
208000008081
Intestinal Fistula
Diseases
0.000
description
1
206010022699
Intestinal stenosis
Diseases
0.000
description
1
206010023198
Joint ankylosis
Diseases
0.000
description
1
208000012659
Joint disease
Diseases
0.000
description
1
ODKSFYDXXFIFQN-BYPYZUCNSA-N
L-arginine
Chemical compound
OC(=O)[C@@H](N)CCCN=C(N)N
ODKSFYDXXFIFQN-BYPYZUCNSA-N
0.000
description
1
229930064664
L-arginine
Natural products
0.000
description
1
235000014852
L-arginine
Nutrition
0.000
description
1
WHUUTDBJXJRKMK-VKHMYHEASA-N
L-glutamic acid
Chemical compound
OC(=O)[C@@H](N)CCC(O)=O
WHUUTDBJXJRKMK-VKHMYHEASA-N
0.000
description
1
239000012097
Lipofectamine 2000
Substances
0.000
description
1
108090001030
Lipoproteins
Proteins
0.000
description
1
102000004895
Lipoproteins
Human genes
0.000
description
1
208000004852
Lung Injury
Diseases
0.000
description
1
208000032376
Lung infection
Diseases
0.000
description
1
208000005777
Lupus Nephritis
Diseases
0.000
description
1
206010062049
Lymphocytic infiltration
Diseases
0.000
description
1
108090000362
Lymphotoxin-beta
Proteins
0.000
description
1
102100026894
Lymphotoxin-beta
Human genes
0.000
description
1
102000043136
MAP kinase family
Human genes
0.000
description
1
108091054455
MAP kinase family
Proteins
0.000
description
1
VJGFOYBQOIPQFY-XMMPIXPASA-N
Mapracorat
Chemical compound
C([C@@](O)(CNC=1C2=CC=C(N=C2C=CC=1)C)C(F)(F)F)C(C)(C)C1=CC(F)=CC2=C1OCC2
VJGFOYBQOIPQFY-XMMPIXPASA-N
0.000
description
1
108010047230
Member 1 Subfamily B ATP Binding Cassette Transporter
Proteins
0.000
description
1
241000699673
Mesocricetus auratus
Species
0.000
description
1
208000019695
Migraine disease
Diseases
0.000
description
1
108010091751
Mitochondrial Aspartate Aminotransferase
Proteins
0.000
description
1
TXXHDPDFNKHHGW-CCAGOZQPSA-N
Muconic acid
Natural products
OC(=O)\C=C/C=C\C(O)=O
TXXHDPDFNKHHGW-CCAGOZQPSA-N
0.000
description
1
108090001099
Multi drug resistance-associated proteins
Proteins
0.000
description
1
102000004855
Multi drug resistance-associated proteins
Human genes
0.000
description
1
101000830602
Mus musculus Tumor necrosis factor ligand superfamily member 11
Proteins
0.000
description
1
206010028289
Muscle atrophy
Diseases
0.000
description
1
241000238367
Mya arenaria
Species
0.000
description
1
208000009525
Myocarditis
Diseases
0.000
description
1
MBBZMMPHUWSWHV-BDVNFPICSA-N
N-methylglucamine
Chemical compound
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
MBBZMMPHUWSWHV-BDVNFPICSA-N
0.000
description
1
101710104636
NADPH:quinone oxidoreductase
Proteins
0.000
description
1
238000005481
NMR spectroscopy
Methods
0.000
description
1
206010061309
Neoplasm progression
Diseases
0.000
description
1
208000012902
Nervous system disease
Diseases
0.000
description
1
206010029260
Neuroblastoma
Diseases
0.000
description
1
208000025966
Neurological disease
Diseases
0.000
description
1
GRYLNZFGIOXLOG-UHFFFAOYSA-N
Nitric acid
Chemical compound
O[N+]([O-])=O
GRYLNZFGIOXLOG-UHFFFAOYSA-N
0.000
description
1
239000000020
Nitrocellulose
Substances
0.000
description
1
238000003725
ONE-Glo Luciferase Assay System
Methods
0.000
description
1
AHLPHDHHMVZTML-UHFFFAOYSA-N
Orn-delta-NH2
Natural products
NCCCC(N)C(O)=O
AHLPHDHHMVZTML-UHFFFAOYSA-N
0.000
description
1
208000031481
Pathologic Constriction
Diseases
0.000
description
1
241001494479
Pecora
Species
0.000
description
1
208000018262
Peripheral vascular disease
Diseases
0.000
description
1
OAICVXFJPJFONN-UHFFFAOYSA-N
Phosphorus
Chemical compound
[P]
OAICVXFJPJFONN-UHFFFAOYSA-N
0.000
description
1
241001482237
Pica
Species
0.000
description
1
108010001014
Plasminogen Activators
Proteins
0.000
description
1
102000001938
Plasminogen Activators
Human genes
0.000
description
1
229920001213
Polysorbate 20
Polymers
0.000
description
1
206010036774
Proctitis
Diseases
0.000
description
1
206010067063
Progressive relapsing multiple sclerosis
Diseases
0.000
description
1
208000003251
Pruritus
Diseases
0.000
description
1
208000028017
Psychotic disease
Diseases
0.000
description
1
206010037660
Pyrexia
Diseases
0.000
description
1
IWYDHOAUDWTVEP-UHFFFAOYSA-N
R-2-phenyl-2-hydroxyacetic acid
Natural products
OC(=O)C(O)C1=CC=CC=C1
IWYDHOAUDWTVEP-UHFFFAOYSA-N
0.000
description
1
101100123093
Rattus norvegicus Gsta2 gene
Proteins
0.000
description
1
241000242739
Renilla
Species
0.000
description
1
108700008625
Reporter Genes
Proteins
0.000
description
1
102000002278
Ribosomal Proteins
Human genes
0.000
description
1
108010000605
Ribosomal Proteins
Proteins
0.000
description
1
BUGBHKTXTAQXES-UHFFFAOYSA-N
Selenium
Chemical group
[Se]
BUGBHKTXTAQXES-UHFFFAOYSA-N
0.000
description
1
206010070834
Sensitisation
Diseases
0.000
description
1
206010040070
Septic Shock
Diseases
0.000
description
1
201000003176
Severe Acute Respiratory Syndrome
Diseases
0.000
description
1
238000012311
Shapiro-Wilk normality test
Methods
0.000
description
1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N
Silicon
Chemical group
[Si]
XUIMIQQOPSSXEZ-UHFFFAOYSA-N
0.000
description
1
DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical compound
[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
description
1
208000005392
Spasm
Diseases
0.000
description
1
208000035286
Spontaneous Remission
Diseases
0.000
description
1
235000021355
Stearic acid
Nutrition
0.000
description
1
108010023197
Streptokinase
Proteins
0.000
description
1
208000032851
Subarachnoid Hemorrhage
Diseases
0.000
description
1
KDYFGRWQOYBRFD-UHFFFAOYSA-N
Succinic acid
Natural products
OC(=O)CCC(O)=O
KDYFGRWQOYBRFD-UHFFFAOYSA-N
0.000
description
1
NINIDFKCEFEMDL-UHFFFAOYSA-N
Sulfur
Chemical compound
[S]
NINIDFKCEFEMDL-UHFFFAOYSA-N
0.000
description
1
108010021188
Superoxide Dismutase-1
Proteins
0.000
description
1
102000008221
Superoxide Dismutase-1
Human genes
0.000
description
1
241000282898
Sus scrofa
Species
0.000
description
1
206010042674
Swelling
Diseases
0.000
description
1
FEWJPZIEWOKRBE-UHFFFAOYSA-N
Tartaric acid
Natural products
[H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O
FEWJPZIEWOKRBE-UHFFFAOYSA-N
0.000
description
1
229940123237
Taxane
Drugs
0.000
description
1
208000007536
Thrombosis
Diseases
0.000
description
1
208000009205
Tinnitus
Diseases
0.000
description
1
102000003929
Transaminases
Human genes
0.000
description
1
206010069363
Traumatic lung injury
Diseases
0.000
description
1
GSEJCLTVZPLZKY-UHFFFAOYSA-N
Triethanolamine
Chemical compound
OCCN(CCO)CCO
GSEJCLTVZPLZKY-UHFFFAOYSA-N
0.000
description
1
YZCKVEUIGOORGS-NJFSPNSNSA-N
Tritium
Chemical compound
[3H]
YZCKVEUIGOORGS-NJFSPNSNSA-N
0.000
description
1
239000013504
Triton X-100
Substances
0.000
description
1
229920004890
Triton X-100
Polymers
0.000
description
1
241001024096
Uleiota
Species
0.000
description
1
241000051616
Ulmus minor
Species
0.000
description
1
XCCTYIAWTASOJW-XVFCMESISA-N
Uridine-5'-Diphosphate
Chemical compound
O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1
XCCTYIAWTASOJW-XVFCMESISA-N
0.000
description
1
208000036142
Viral infection
Diseases
0.000
description
1
244000126002
Ziziphus vulgaris
Species
0.000
description
1
235000008529
Ziziphus vulgaris
Nutrition
0.000
description
1
SORGEQQSQGNZFI-UHFFFAOYSA-N
[azido(phenoxy)phosphoryl]oxybenzene
Chemical compound
C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1
SORGEQQSQGNZFI-UHFFFAOYSA-N
0.000
description
1
230000001594
aberrant effect
Effects
0.000
description
1
238000002679
ablation
Methods
0.000
description
1
230000035508
accumulation
Effects
0.000
description
1
238000009825
accumulation
Methods
0.000
description
1
150000001242
acetic acid derivatives
Chemical class
0.000
description
1
230000002378
acidificating effect
Effects
0.000
description
1
231100000569
acute exposure
Toxicity
0.000
description
1
208000005298
acute pain
Diseases
0.000
description
1
208000012998
acute renal failure
Diseases
0.000
description
1
210000001789
adipocyte
Anatomy
0.000
description
1
210000000577
adipose tissue
Anatomy
0.000
description
1
239000000443
aerosol
Substances
0.000
description
1
229960000548
alemtuzumab
Drugs
0.000
description
1
208000026935
allergic disease
Diseases
0.000
description
1
230000007815
allergy
Effects
0.000
description
1
BJEPYKJPYRNKOW-UHFFFAOYSA-N
alpha-hydroxysuccinic acid
Natural products
OC(=O)C(O)CC(O)=O
BJEPYKJPYRNKOW-UHFFFAOYSA-N
0.000
description
1
229910000147
aluminium phosphate
Inorganic materials
0.000
description
1
150000001408
amides
Chemical class
0.000
description
1
150000001412
amines
Chemical class
0.000
description
1
229940024606
amino acid
Drugs
0.000
description
1
235000001014
amino acid
Nutrition
0.000
description
1
150000001413
amino acids
Chemical class
0.000
description
1
125000003277
amino group
Chemical group
0.000
description
1
230000036783
anaphylactic response
Effects
0.000
description
1
208000003455
anaphylaxis
Diseases
0.000
description
1
239000003098
androgen
Substances
0.000
description
1
208000007502
anemia
Diseases
0.000
description
1
230000033115
angiogenesis
Effects
0.000
description
1
238000002399
angioplasty
Methods
0.000
description
1
239000005557
antagonist
Substances
0.000
description
1
229940045799
anthracyclines and related substance
Drugs
0.000
description
1
230000001093
anti-cancer
Effects
0.000
description
1
230000003217
anti-cancerogenic effect
Effects
0.000
description
1
230000003092
anti-cytokine
Effects
0.000
description
1
230000005809
anti-tumor immunity
Effects
0.000
description
1
239000003146
anticoagulant agent
Substances
0.000
description
1
229940127219
anticoagulant drug
Drugs
0.000
description
1
210000000436
anus
Anatomy
0.000
description
1
238000013459
approach
Methods
0.000
description
1
239000012062
aqueous buffer
Substances
0.000
description
1
239000012736
aqueous medium
Substances
0.000
description
1
239000008346
aqueous phase
Substances
0.000
description
1
229940114078
arachidonate
Drugs
0.000
description
1
ODKSFYDXXFIFQN-UHFFFAOYSA-N
arginine
Natural products
OC(=O)C(N)CCCNC(N)=N
ODKSFYDXXFIFQN-UHFFFAOYSA-N
0.000
description
1
235000009697
arginine
Nutrition
0.000
description
1
230000004872
arterial blood pressure
Effects
0.000
description
1
210000001130
astrocyte
Anatomy
0.000
description
1
230000003140
astrocytic effect
Effects
0.000
description
1
QVGXLLKOCUKJST-UHFFFAOYSA-N
atomic oxygen
Chemical compound
[O]
QVGXLLKOCUKJST-UHFFFAOYSA-N
0.000
description
1
230000010455
autoregulation
Effects
0.000
description
1
229940120638
avastin
Drugs
0.000
description
1
125000000852
azido group
Chemical group
*N=[N+]=[N-]
0.000
description
1
229950002483
bardoxolone
Drugs
0.000
description
1
239000011324
bead
Substances
0.000
description
1
230000003542
behavioural effect
Effects
0.000
description
1
229940092714
benzenesulfonic acid
Drugs
0.000
description
1
GONOPSZTUGRENK-UHFFFAOYSA-N
benzyl(trichloro)silane
Chemical compound
Cl[Si](Cl)(Cl)CC1=CC=CC=C1
GONOPSZTUGRENK-UHFFFAOYSA-N
0.000
description
1
QBUVFDKTZJNUPP-UHFFFAOYSA-N
biliverdin-IXalpha
Natural products
N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1
QBUVFDKTZJNUPP-UHFFFAOYSA-N
0.000
description
1
238000004638
bioanalytical method
Methods
0.000
description
1
230000033228
biological regulation
Effects
0.000
description
1
229960004395
bleomycin sulfate
Drugs
0.000
description
1
210000001124
body fluid
Anatomy
0.000
description
1
230000014461
bone development
Effects
0.000
description
1
230000010072
bone remodeling
Effects
0.000
description
1
230000004641
brain development
Effects
0.000
description
1
210000005013
brain tissue
Anatomy
0.000
description
1
201000008275
breast carcinoma
Diseases
0.000
description
1
239000006189
buccal tablet
Substances
0.000
description
1
SNPPWIUOZRMYNY-UHFFFAOYSA-N
bupropion
Chemical compound
CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1
SNPPWIUOZRMYNY-UHFFFAOYSA-N
0.000
description
1
229960001058
bupropion
Drugs
0.000
description
1
KDYFGRWQOYBRFD-NUQCWPJISA-N
butanedioic acid
Chemical compound
O[14C](=O)CC[14C](O)=O
KDYFGRWQOYBRFD-NUQCWPJISA-N
0.000
description
1
239000006227
byproduct
Substances
0.000
description
1
AXCZMVOFGPJBDE-UHFFFAOYSA-L
calcium dihydroxide
Chemical compound
[OH-].[OH-].[Ca+2]
AXCZMVOFGPJBDE-UHFFFAOYSA-L
0.000
description
1
239000000920
calcium hydroxide
Substances
0.000
description
1
229910001861
calcium hydroxide
Inorganic materials
0.000
description
1
229940112129
campath
Drugs
0.000
description
1
230000009702
cancer cell proliferation
Effects
0.000
description
1
230000036952
cancer formation
Effects
0.000
description
1
230000000711
cancerogenic effect
Effects
0.000
description
1
239000002775
capsule
Substances
0.000
description
1
239000007963
capsule composition
Substances
0.000
description
1
239000004202
carbamide
Substances
0.000
description
1
BVKZGUZCCUSVTD-UHFFFAOYSA-N
carbonic acid
Chemical compound
OC(O)=O
BVKZGUZCCUSVTD-UHFFFAOYSA-N
0.000
description
1
125000002915
carbonyl group
Chemical group
[*:2]C([*:1])=O
0.000
description
1
150000001732
carboxylic acid derivatives
Chemical class
0.000
description
1
231100000357
carcinogen
Toxicity
0.000
description
1
239000003183
carcinogenic agent
Substances
0.000
description
1
230000009084
cardiovascular function
Effects
0.000
description
1
210000000748
cardiovascular system
Anatomy
0.000
description
1
210000000845
cartilage
Anatomy
0.000
description
1
230000015556
catabolic process
Effects
0.000
description
1
230000003197
catalytic effect
Effects
0.000
description
1
229960000590
celecoxib
Drugs
0.000
description
1
RZEKVGVHFLEQIL-UHFFFAOYSA-N
celecoxib
Chemical compound
C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1
RZEKVGVHFLEQIL-UHFFFAOYSA-N
0.000
description
1
239000006143
cell culture medium
Substances
0.000
description
1
230000024245
cell differentiation
Effects
0.000
description
1
230000036755
cellular response
Effects
0.000
description
1
230000007541
cellular toxicity
Effects
0.000
description
1
239000001913
cellulose
Substances
0.000
description
1
229920002678
cellulose
Polymers
0.000
description
1
201000006662
cervical adenocarcinoma
Diseases
0.000
description
1
125000003636
chemical group
Chemical group
0.000
description
1
238000001311
chemical methods and process
Methods
0.000
description
1
238000007385
chemical modification
Methods
0.000
description
1
231100000481
chemical toxicant
Toxicity
0.000
description
1
230000002113
chemopreventative effect
Effects
0.000
description
1
230000000973
chemotherapeutic effect
Effects
0.000
description
1
230000002759
chromosomal effect
Effects
0.000
description
1
229960001265
ciclosporin
Drugs
0.000
description
1
235000013985
cinnamic acid
Nutrition
0.000
description
1
229930016911
cinnamic acid
Natural products
0.000
description
1
230000004087
circulation
Effects
0.000
description
1
150000001860
citric acid derivatives
Chemical class
0.000
description
1
229960002173
citrulline
Drugs
0.000
description
1
238000010367
cloning
Methods
0.000
description
1
206010009887
colitis
Diseases
0.000
description
1
208000029742
colonic neoplasm
Diseases
0.000
description
1
239000003086
colorant
Substances
0.000
description
1
238000011284
combination treatment
Methods
0.000
description
1
230000002301
combined effect
Effects
0.000
description
1
238000013329
compounding
Methods
0.000
description
1
230000001010
compromised effect
Effects
0.000
description
1
230000001143
conditioned effect
Effects
0.000
description
1
208000028831
congenital heart disease
Diseases
0.000
description
1
230000021615
conjugation
Effects
0.000
description
1
239000000470
constituent
Substances
0.000
description
1
229940039231
contrast media
Drugs
0.000
description
1
210000004087
cornea
Anatomy
0.000
description
1
210000004351
coronary vessel
Anatomy
0.000
description
1
229940109239
creatinine
Drugs
0.000
description
1
239000013078
crystal
Substances
0.000
description
1
230000001186
cumulative effect
Effects
0.000
description
1
HCAJEUSONLESMK-UHFFFAOYSA-N
cyclohexylsulfamic acid
Chemical class
OS(=O)(=O)NC1CCCCC1
HCAJEUSONLESMK-UHFFFAOYSA-N
0.000
description
1
229930182912
cyclosporin
Natural products
0.000
description
1
125000000151
cysteine group
Chemical group
N[C@@H](CS)C(=O)*
0.000
description
1
230000034994
death
Effects
0.000
description
1
238000000354
decomposition reaction
Methods
0.000
description
1
230000007812
deficiency
Effects
0.000
description
1
230000002950
deficient
Effects
0.000
description
1
230000018044
dehydration
Effects
0.000
description
1
238000006297
dehydration reaction
Methods
0.000
description
1
108010017271
denileukin diftitox
Proteins
0.000
description
1
238000004807
desolvation
Methods
0.000
description
1
230000001066
destructive effect
Effects
0.000
description
1
238000001514
detection method
Methods
0.000
description
1
238000001784
detoxification
Methods
0.000
description
1
230000001627
detrimental effect
Effects
0.000
description
1
229910052805
deuterium
Inorganic materials
0.000
description
1
208000033679
diabetic kidney disease
Diseases
0.000
description
1
238000002059
diagnostic imaging
Methods
0.000
description
1
230000003205
diastolic effect
Effects
0.000
description
1
150000001991
dicarboxylic acids
Chemical class
0.000
description
1
235000005911
diet
Nutrition
0.000
description
1
230000037213
diet
Effects
0.000
description
1
ZBCBWPMODOFKDW-UHFFFAOYSA-N
diethanolamine
Chemical compound
OCCNCCO
ZBCBWPMODOFKDW-UHFFFAOYSA-N
0.000
description
1
150000004683
dihydrates
Chemical class
0.000
description
1
230000003292
diminished effect
Effects
0.000
description
1
230000009266
disease activity
Effects
0.000
description
1
235000014632
disordered eating
Nutrition
0.000
description
1
239000002612
dispersion medium
Substances
0.000
description
1
MOTZDAYCYVMXPC-UHFFFAOYSA-N
dodecyl hydrogen sulfate
Chemical compound
CCCCCCCCCCCCOS(O)(=O)=O
MOTZDAYCYVMXPC-UHFFFAOYSA-N
0.000
description
1
239000002552
dosage form
Substances
0.000
description
1
230000002222
downregulating effect
Effects
0.000
description
1
230000008406
drug-drug interaction
Effects
0.000
description
1
210000001198
duodenum
Anatomy
0.000
description
1
230000004064
dysfunction
Effects
0.000
description
1
230000002900
effect on cell
Effects
0.000
description
1
239000003792
electrolyte
Substances
0.000
description
1
238000002001
electrophysiology
Methods
0.000
description
1
230000007831
electrophysiology
Effects
0.000
description
1
206010014665
endocarditis
Diseases
0.000
description
1
230000008694
endothelial dysfunction
Effects
0.000
description
1
210000003038
endothelium
Anatomy
0.000
description
1
238000011067
equilibration
Methods
0.000
description
1
230000003628
erosive effect
Effects
0.000
description
1
229960001842
estramustine
Drugs
0.000
description
1
FRPJXPJMRWBBIH-RBRWEJTLSA-N
estramustine
Chemical compound
ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1
FRPJXPJMRWBBIH-RBRWEJTLSA-N
0.000
description
1
AFAXGSQYZLGZPG-UHFFFAOYSA-N
ethanedisulfonic acid
Chemical compound
OS(=O)(=O)CCS(O)(=O)=O
AFAXGSQYZLGZPG-UHFFFAOYSA-N
0.000
description
1
CCIVGXIOQKPBKL-UHFFFAOYSA-M
ethanesulfonate
Chemical compound
CCS([O-])(=O)=O
CCIVGXIOQKPBKL-UHFFFAOYSA-M
0.000
description
1
CCIVGXIOQKPBKL-UHFFFAOYSA-N
ethanesulfonic acid
Chemical class
CCS(O)(=O)=O
CCIVGXIOQKPBKL-UHFFFAOYSA-N
0.000
description
1
150000002170
ethers
Chemical class
0.000
description
1
238000001704
evaporation
Methods
0.000
description
1
230000008020
evaporation
Effects
0.000
description
1
230000003203
everyday effect
Effects
0.000
description
1
201000005884
exanthem
Diseases
0.000
description
1
210000003499
exocrine gland
Anatomy
0.000
description
1
230000036251
extravasation
Effects
0.000
description
1
230000001605
fetal effect
Effects
0.000
description
1
210000003754
fetus
Anatomy
0.000
description
1
239000000706
filtrate
Substances
0.000
description
1
210000004905
finger nail
Anatomy
0.000
description
1
230000003890
fistula
Effects
0.000
description
1
238000000684
flow cytometry
Methods
0.000
description
1
230000003325
follicular
Effects
0.000
description
1
230000037406
food intake
Effects
0.000
description
1
235000012631
food intake
Nutrition
0.000
description
1
VZCYOOQTPOCHFL-OWOJBTEDSA-L
fumarate(2-)
Chemical class
[O-]C(=O)\C=C\C([O-])=O
VZCYOOQTPOCHFL-OWOJBTEDSA-L
0.000
description
1
239000001530
fumaric acid
Substances
0.000
description
1
125000000524
functional group
Chemical group
0.000
description
1
229940044627
gamma-interferon
Drugs
0.000
description
1
208000030304
gastrointestinal bleeding
Diseases
0.000
description
1
210000005095
gastrointestinal system
Anatomy
0.000
description
1
210000001035
gastrointestinal tract
Anatomy
0.000
description
1
239000007903
gelatin capsule
Substances
0.000
description
1
230000002068
genetic effect
Effects
0.000
description
1
230000004914
glial activation
Effects
0.000
description
1
210000000585
glomerular basement membrane
Anatomy
0.000
description
1
230000024924
glomerular filtration
Effects
0.000
description
1
239000000174
gluconic acid
Substances
0.000
description
1
235000012208
gluconic acid
Nutrition
0.000
description
1
230000004190
glucose uptake
Effects
0.000
description
1
230000023611
glucuronidation
Effects
0.000
description
1
235000013922
glutamic acid
Nutrition
0.000
description
1
239000004220
glutamic acid
Substances
0.000
description
1
230000006545
glycolytic metabolism
Effects
0.000
description
1
208000035474
group of disease
Diseases
0.000
description
1
230000012010
growth
Effects
0.000
description
1
239000003102
growth factor
Substances
0.000
description
1
150000003278
haem
Chemical class
0.000
description
1
230000003394
haemopoietic effect
Effects
0.000
description
1
230000009931
harmful effect
Effects
0.000
description
1
230000036541
health
Effects
0.000
description
1
230000011132
hemopoiesis
Effects
0.000
description
1
206010073071
hepatocellular carcinoma
Diseases
0.000
description
1
229940022353
herceptin
Drugs
0.000
description
1
210000004394
hip joint
Anatomy
0.000
description
1
230000002962
histologic effect
Effects
0.000
description
1
238000010562
histological examination
Methods
0.000
description
1
238000009396
hybridization
Methods
0.000
description
1
125000004356
hydroxy functional group
Chemical group
O*
0.000
description
1
125000002887
hydroxy group
Chemical group
[H]O*
0.000
description
1
125000002349
hydroxyamino group
Chemical group
[H]ON([H])[*]
0.000
description
1
230000000222
hyperoxic effect
Effects
0.000
description
1
201000005991
hyperphosphatemia
Diseases
0.000
description
1
208000006575
hypertriglyceridemia
Diseases
0.000
description
1
230000007954
hypoxia
Effects
0.000
description
1
229960001680
ibuprofen
Drugs
0.000
description
1
239000012216
imaging agent
Substances
0.000
description
1
238000003384
imaging method
Methods
0.000
description
1
230000008076
immune mechanism
Effects
0.000
description
1
230000001771
impaired effect
Effects
0.000
description
1
238000000099
in vitro assay
Methods
0.000
description
1
238000005462
in vivo assay
Methods
0.000
description
1
230000002779
inactivation
Effects
0.000
description
1
108700016226
indium-bleomycin
Proteins
0.000
description
1
239000003701
inert diluent
Substances
0.000
description
1
210000004969
inflammatory cell
Anatomy
0.000
description
1
150000002484
inorganic compounds
Chemical class
0.000
description
1
229910010272
inorganic material
Inorganic materials
0.000
description
1
230000010354
integration
Effects
0.000
description
1
229960003130
interferon gamma
Drugs
0.000
description
1
208000028774
intestinal disease
Diseases
0.000
description
1
230000006525
intracellular process
Effects
0.000
description
1
238000010253
intravenous injection
Methods
0.000
description
1
230000009545
invasion
Effects
0.000
description
1
238000011835
investigation
Methods
0.000
description
1
210000000554
iris
Anatomy
0.000
description
1
229910052742
iron
Inorganic materials
0.000
description
1
230000002427
irreversible effect
Effects
0.000
description
1
230000007794
irritation
Effects
0.000
description
1
230000000302
ischemic effect
Effects
0.000
description
1
210000004153
islets of langerhan
Anatomy
0.000
description
1
239000012948
isocyanate
Substances
0.000
description
1
150000002513
isocyanates
Chemical class
0.000
description
1
238000002955
isolation
Methods
0.000
description
1
230000000155
isotopic effect
Effects
0.000
description
1
230000003907
kidney function
Effects
0.000
description
1
210000003127
knee
Anatomy
0.000
description
1
150000003893
lactate salts
Chemical class
0.000
description
1
239000004310
lactic acid
Substances
0.000
description
1
235000014655
lactic acid
Nutrition
0.000
description
1
210000002414
leg
Anatomy
0.000
description
1
231100001231
less toxic
Toxicity
0.000
description
1
210000003041
ligament
Anatomy
0.000
description
1
239000003446
ligand
Substances
0.000
description
1
239000007788
liquid
Substances
0.000
description
1
230000033001
locomotion
Effects
0.000
description
1
238000003670
luciferase enzyme activity assay
Methods
0.000
description
1
231100000515
lung injury
Toxicity
0.000
description
1
210000004698
lymphocyte
Anatomy
0.000
description
1
239000012139
lysis buffer
Substances
0.000
description
1
238000012423
maintenance
Methods
0.000
description
1
VZCYOOQTPOCHFL-UPHRSURJSA-N
maleic acid
Chemical compound
OC(=O)\C=C/C(O)=O
VZCYOOQTPOCHFL-UPHRSURJSA-N
0.000
description
1
239000011976
maleic acid
Substances
0.000
description
1
150000002688
maleic acid derivatives
Chemical class
0.000
description
1
239000001630
malic acid
Substances
0.000
description
1
235000011090
malic acid
Nutrition
0.000
description
1
150000002690
malonic acid derivatives
Chemical class
0.000
description
1
210000004962
mammalian cell
Anatomy
0.000
description
1
229960002510
mandelic acid
Drugs
0.000
description
1
229950001567
mapracorat
Drugs
0.000
description
1
229940087412
maxidex
Drugs
0.000
description
1
239000002609
medium
Substances
0.000
description
1
229960004963
mesalazine
Drugs
0.000
description
1
210000003584
mesangial cell
Anatomy
0.000
description
1
230000002503
metabolic effect
Effects
0.000
description
1
AFVFQIVMOAPDHO-UHFFFAOYSA-M
methanesulfonate group
Chemical class
CS(=O)(=O)[O-]
AFVFQIVMOAPDHO-UHFFFAOYSA-M
0.000
description
1
229940098779
methanesulfonic acid
Drugs
0.000
description
1
150000004702
methyl esters
Chemical class
0.000
description
1
WBYWAXJHAXSJNI-UHFFFAOYSA-N
methyl p-hydroxycinnamate
Natural products
OC(=O)C=CC1=CC=CC=C1
WBYWAXJHAXSJNI-UHFFFAOYSA-N
0.000
description
1
230000006724
microglial activation
Effects
0.000
description
1
206010027599
migraine
Diseases
0.000
description
1
150000007522
mineralic acids
Chemical class
0.000
description
1
230000004065
mitochondrial dysfunction
Effects
0.000
description
1
230000009456
molecular mechanism
Effects
0.000
description
1
210000001616
monocyte
Anatomy
0.000
description
1
150000004682
monohydrates
Chemical class
0.000
description
1
210000005087
mononuclear cell
Anatomy
0.000
description
1
238000007837
multiplex assay
Methods
0.000
description
1
238000012314
multivariate regression analysis
Methods
0.000
description
1
206010028320
muscle necrosis
Diseases
0.000
description
1
201000000585
muscular atrophy
Diseases
0.000
description
1
239000003471
mutagenic agent
Substances
0.000
description
1
231100000707
mutagenic chemical
Toxicity
0.000
description
1
230000003505
mutagenic effect
Effects
0.000
description
1
210000000066
myeloid cell
Anatomy
0.000
description
1
FUZZWVXGSFPDMH-UHFFFAOYSA-N
n-hexanoic acid
Natural products
CCCCCC(O)=O
FUZZWVXGSFPDMH-UHFFFAOYSA-N
0.000
description
1
229950006238
nadide
Drugs
0.000
description
1
KVBGVZZKJNLNJU-UHFFFAOYSA-N
naphthalene-2-sulfonic acid
Chemical compound
C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21
KVBGVZZKJNLNJU-UHFFFAOYSA-N
0.000
description
1
230000009707
neogenesis
Effects
0.000
description
1
210000000653
nervous system
Anatomy
0.000
description
1
210000002241
neurite
Anatomy
0.000
description
1
210000002569
neuron
Anatomy
0.000
description
1
230000009223
neuronal apoptosis
Effects
0.000
description
1
230000003955
neuronal function
Effects
0.000
description
1
229910017604
nitric acid
Inorganic materials
0.000
description
1
125000000449
nitro group
Chemical group
[O-][N+](*)=O
0.000
description
1
229920001220
nitrocellulos
Polymers
0.000
description
1
229910052757
nitrogen
Inorganic materials
0.000
description
1
125000004433
nitrogen atom
Chemical class
N*
0.000
description
1
239000000041
non-steroidal anti-inflammatory agent
Substances
0.000
description
1
229940021182
non-steroidal anti-inflammatory drug
Drugs
0.000
description
1
238000010606
normalization
Methods
0.000
description
1
QIQXTHQIDYTFRH-UHFFFAOYSA-N
octadecanoic acid
Chemical compound
CCCCCCCCCCCCCCCCCC(O)=O
QIQXTHQIDYTFRH-UHFFFAOYSA-N
0.000
description
1
OQCDKBAXFALNLD-UHFFFAOYSA-N
octadecanoic acid
Natural products
CCCCCCCC(C)CCCCCCCCC(O)=O
OQCDKBAXFALNLD-UHFFFAOYSA-N
0.000
description
1
229940100027
ontak
Drugs
0.000
description
1
230000003287
optical effect
Effects
0.000
description
1
230000008816
organ damage
Effects
0.000
description
1
210000004789
organ system
Anatomy
0.000
description
1
150000007524
organic acids
Chemical class
0.000
description
1
235000005985
organic acids
Nutrition
0.000
description
1
150000002891
organic anions
Chemical class
0.000
description
1
239000012074
organic phase
Substances
0.000
description
1
239000003960
organic solvent
Substances
0.000
description
1
229960003104
ornithine
Drugs
0.000
description
1
238000012261
overproduction
Methods
0.000
description
1
150000003891
oxalate salts
Chemical class
0.000
description
1
235000006408
oxalic acid
Nutrition
0.000
description
1
230000004792
oxidative damage
Effects
0.000
description
1
229910052760
oxygen
Inorganic materials
0.000
description
1
239000001301
oxygen
Substances
0.000
description
1
125000004430
oxygen atom
Chemical group
O*
0.000
description
1
FJKROLUGYXJWQN-UHFFFAOYSA-N
papa-hydroxy-benzoic acid
Natural products
OC(=O)C1=CC=C(O)C=C1
FJKROLUGYXJWQN-UHFFFAOYSA-N
0.000
description
1
229960005489
paracetamol
Drugs
0.000
description
1
230000003071
parasitic effect
Effects
0.000
description
1
238000007911
parenteral administration
Methods
0.000
description
1
244000052769
pathogen
Species
0.000
description
1
230000001717
pathogenic effect
Effects
0.000
description
1
229960005079
pemetrexed
Drugs
0.000
description
1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N
pemetrexed
Chemical compound
C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N
0.000
description
1
239000000813
peptide hormone
Substances
0.000
description
1
230000002085
persistent effect
Effects
0.000
description
1
239000000546
pharmaceutical excipient
Substances
0.000
description
1
229960003893
phenacetin
Drugs
0.000
description
1
150000003013
phosphoric acid derivatives
Chemical class
0.000
description
1
229910052698
phosphorus
Inorganic materials
0.000
description
1
239000011574
phosphorus
Substances
0.000
description
1
230000035790
physiological processes and functions
Effects
0.000
description
1
IUGYQRQAERSCNH-UHFFFAOYSA-N
pivalic acid
Chemical compound
CC(C)(C)C(O)=O
IUGYQRQAERSCNH-UHFFFAOYSA-N
0.000
description
1
239000000902
placebo
Substances
0.000
description
1
229940068196
placebo
Drugs
0.000
description
1
229940127126
plasminogen activator
Drugs
0.000
description
1
238000007747
plating
Methods
0.000
description
1
239000000256
polyoxyethylene sorbitan monolaurate
Substances
0.000
description
1
235000010486
polyoxyethylene sorbitan monolaurate
Nutrition
0.000
description
1
239000013641
positive control
Substances
0.000
description
1
230000029279
positive regulation of transcription, DNA-dependent
Effects
0.000
description
1
208000028173
post-traumatic stress disease
Diseases
0.000
description
1
WSHYKIAQCMIPTB-UHFFFAOYSA-M
potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate
Chemical compound
[K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1
WSHYKIAQCMIPTB-UHFFFAOYSA-M
0.000
description
1
239000003755
preservative agent
Substances
0.000
description
1
230000002335
preservative effect
Effects
0.000
description
1
125000002924
primary amino group
Chemical group
[H]N([H])*
0.000
description
1
238000004393
prognosis
Methods
0.000
description
1
230000008741
proinflammatory signaling process
Effects
0.000
description
1
235000019260
propionic acid
Nutrition
0.000
description
1
UQOQENZZLBSFKO-POPPZSFYSA-N
prostaglandin J2
Chemical compound
CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O
UQOQENZZLBSFKO-POPPZSFYSA-N
0.000
description
1
210000005267
prostate cell
Anatomy
0.000
description
1
229940034080
provenge
Drugs
0.000
description
1
230000001185
psoriatic effect
Effects
0.000
description
1
229940107700
pyruvic acid
Drugs
0.000
description
1
238000011002
quantification
Methods
0.000
description
1
238000011158
quantitative evaluation
Methods
0.000
description
1
IUVKMZGDUIUOCP-BTNSXGMBSA-N
quinbolone
Chemical compound
O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1
IUVKMZGDUIUOCP-BTNSXGMBSA-N
0.000
description
1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N
rapamycin
Natural products
COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C
ZAHRKKWIAAJSAO-UHFFFAOYSA-N
0.000
description
1
206010037844
rash
Diseases
0.000
description
1
239000007845
reactive nitrogen species
Substances
0.000
description
1
108091006084
receptor activators
Proteins
0.000
description
1
210000000664
rectum
Anatomy
0.000
description
1
230000001172
regenerating effect
Effects
0.000
description
1
230000022983
regulation of cell cycle
Effects
0.000
description
1
230000022532
regulation of transcription, DNA-dependent
Effects
0.000
description
1
230000008844
regulatory mechanism
Effects
0.000
description
1
230000008327
renal blood flow
Effects
0.000
description
1
230000008085
renal dysfunction
Effects
0.000
description
1
230000008439
repair process
Effects
0.000
description
1
238000011160
research
Methods
0.000
description
1
230000000241
respiratory effect
Effects
0.000
description
1
230000036387
respiratory rate
Effects
0.000
description
1
210000002345
respiratory system
Anatomy
0.000
description
1
208000023504
respiratory system disease
Diseases
0.000
description
1
230000008458
response to injury
Effects
0.000
description
1
208000037803
restenosis
Diseases
0.000
description
1
208000004124
rheumatic heart disease
Diseases
0.000
description
1
210000003131
sacroiliac joint
Anatomy
0.000
description
1
150000003873
salicylate salts
Chemical class
0.000
description
1
229960004889
salicylic acid
Drugs
0.000
description
1
210000003079
salivary gland
Anatomy
0.000
description
1
229920006395
saturated elastomer
Polymers
0.000
description
1
210000004761
scalp
Anatomy
0.000
description
1
230000036573
scar formation
Effects
0.000
description
1
230000037390
scarring
Effects
0.000
description
1
229910052711
selenium
Inorganic materials
0.000
description
1
238000012764
semi-quantitative analysis
Methods
0.000
description
1
230000008313
sensitization
Effects
0.000
description
1
230000001953
sensory effect
Effects
0.000
description
1
230000036303
septic shock
Effects
0.000
description
1
238000010008
shearing
Methods
0.000
description
1
230000035939
shock
Effects
0.000
description
1
210000000323
shoulder joint
Anatomy
0.000
description
1
229910052710
silicon
Inorganic materials
0.000
description
1
238000009097
single-agent therapy
Methods
0.000
description
1
229960000714
sipuleucel-t
Drugs
0.000
description
1
QFJCIRLUMZQUOT-HPLJOQBZSA-N
sirolimus
Chemical compound
C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1
QFJCIRLUMZQUOT-HPLJOQBZSA-N
0.000
description
1
229960002930
sirolimus
Drugs
0.000
description
1
231100000046
skin rash
Toxicity
0.000
description
1
238000010583
slow cooling
Methods
0.000
description
1
150000003384
small molecules
Chemical class
0.000
descr